University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Masters Theses

Graduate School

12-2005

Effect of Dietary Treatment with Stearidonic Acid and
Eicosapentaenoic Acid on Membrane Phospholipid Fatty Acid
Composition and Glycogen-Elicited Peritoneal Neutrophil Survival
in Absence or Presence of Bacterial Endotoxin
Jonathan Earl Phipps
University of Tennessee - Knoxville

Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes
Part of the Alternative and Complementary Medicine Commons

Recommended Citation
Phipps, Jonathan Earl, "Effect of Dietary Treatment with Stearidonic Acid and Eicosapentaenoic Acid on
Membrane Phospholipid Fatty Acid Composition and Glycogen-Elicited Peritoneal Neutrophil Survival in
Absence or Presence of Bacterial Endotoxin. " Master's Thesis, University of Tennessee, 2005.
https://trace.tennessee.edu/utk_gradthes/2296

This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and
Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE:
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu.

To the Graduate Council:
I am submitting herewith a thesis written by Jonathan Earl Phipps entitled "Effect of Dietary
Treatment with Stearidonic Acid and Eicosapentaenoic Acid on Membrane Phospholipid Fatty
Acid Composition and Glycogen-Elicited Peritoneal Neutrophil Survival in Absence or Presence
of Bacterial Endotoxin." I have examined the final electronic copy of this thesis for form and
content and recommend that it be accepted in partial fulfillment of the requirements for the
degree of Master of Science, with a major in Comparative and Experimental Medicine.
Michael D. Karlstad, Major Professor
We have read this thesis and recommend its acceptance:
Joseph W. Bartges, Ph.D., Jay Whelan, Ph.D.
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

To the Graduate Council:
I am submitting herewith a thesis written by Jonathan Earl Phipps entitled “Effect
of Dietary Treatment with Stearidonic Acid and Eicosapentaenoic Acid on
Membrane Phospholipid Fatty Acid Composition and Glycogen-Elicited
Peritoneal Neutrophil Survival in Absence or Presence of Bacterial Endotoxin.” I
have examined the final electronic copy of this thesis for form and content and
recommend that it be accepted in partial fulfillment of the requirements for the
degree of Master of Science, with a major in Comparative and Experimental
Medicine.

Michael D. Karlstad
Major Professor

We have read this thesis and
recommend its acceptance:
Joseph W. Bartges, Ph.D.
Jay Whelan, Ph.D.

Acceptance for the Council:
Anne Mayhew
Vice Chancellor and
Dean of Graduate Studies

(Original signatures are on file with official student records)

Effect of Dietary Treatment with Stearidonic Acid and
Eicosapentaenoic Acid on Membrane Phospholipid Fatty Acid
Composition and Glycogen-Elicited Peritoneal Neutrophil
Survival in Absence or Presence of Bacterial Endotoxin

A Thesis
Presented for the
Master of Science Degree
The University of Tennessee, Knoxville

Jonathan Earl Phipps
December 2005

ii

Dedication
This thesis is dedicated to my mother and father, Larry and Judy Phipps, who
made it their first priority to provide me with the encouragement to accomplish my
goals and dreams; also, to my grandparents; Charles and Louise Phipps,
Charlie and Mardell Brewer; great grandparents, Earl Needham, Helen Brock,
and especially Grace Phipps, all of whom have been beacons of guidance over
the years; to Jada Shadden whose boundless compassion and dedication to her
own dreams has been inspirational; finally, to my family of friends who, although
are too numerous to mention all by name in the space allotted, have given me
the courage and stamina to be where I am today.

iii
Acknowledgements
I wish to thank all of those who took the time and patience to help me along the
way of completing my research. First, I would like to thank my major professor
Dr. Michael Karlstad, who provided me with the opportunity to pursue my
graduate studies, and provided wisdom, friendship, and guidance along the way.
I would also like to thank Dr. Jay Whelan and Dr. Joe Bartges for their
assistance, advice and friendship.
I would also like to thank Dr. Mitchell Goldman, Dr. Blaine Enderson, and Dr.
Brian Daley for their support of my research. I would like to thank Dr. Rob Gillis
for his friendship and support throughout my graduate experience. I would also
like to thank Richard Andrews, Lucy Simpson, Stacy Kirkpatrick, Steve Foster,
Erica Johnson and Laura Jones for their expertise, friendship, and support
throughout the research of this dissertation. I would especially like to thank
Meghan Parrott for her selfless dedication to my research, as well as for her
friendship and support during the endeavor.
Finally, I am grateful to my friends and family for all the love and support that
they have provided over the course of my graduate studies. Above all, I thank
God for the opportunity and blessings that have been provided me.

iv

Abstract
We previously found that enteral nutrition with diets containing elevated
levels of eicosapentaenoic acid (EPA; 20:5 n-3) reduced the number of
neutrophils in bronchoalveolar lavage fluid and improved clinical outcome of
patients with or at risk for adult respiratory distress syndrome (ARDS). We have
also shown that the treatment of the neutrophil-like cell line, HL-60, with EPA can
induce apoptosis. It is not known, however, if the addition of EPA to the diet
would result in similar occurrences in neutrophils.
It has been suggested that the use of diets enriched with stearidonic acid
(SDA; 18:4 n-3) may provide a novel source of n-3 fatty acids while offering
similar beneficial effects on health as diets containing EPA. Therefore, we
examined whether dietary SDA can be used as a precursor to increase EPA
content in liver tissue.
It is well known that endotoxin increases neutrophil lifespan and that this
may be important in maintaining innate immune response. The second part of
this study incorporated the use of glycogen-elicited peritoneal neutrophils from
the rat to examine the effect of dietary intervention with n-3 fatty acids (either
EPA or SDA) on constitutive and endotoxin induced neutrophil survival. Male
Long-Evans rats (n=18) were randomly divided into 3 dietary groups and fed a
modified US-17 diet providing 200kcal/kg/day and containing 2% oleic acid (OA;
18:1 n-9) (n=6), 1% EPA/1% OA (n=6), or 1% SDA/1% OA (n=6) for 2 weeks.
Liver phospholipids were analyzed using gas chromatography and neutrophil
lifespan was evaluated using flow cytometry.
Dietary supplementation with EPA significantly increased the
concentration of EPA and docosapentaenoic acid (DPA, 22:5n3), but not
docosahexaenoic acid (DHA, 22:6n3) in liver tissue as compared with animals
fed OA. Dietary supplementation with SDA also increased tissue contents of
EPA and DPA, but not DHA as compared with OA fed controls. The increase in
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tissue EPA was about one-half as effective in animals fed a diet containing SDA
as those fed EPA. SDA was about two-thirds as effective as EPA at increasing
tissue DPA content. These results indicate that, when fed at current dietary
levels, SDA can increase the incorporation of EPA and DPA into the membrane
phospholipids of liver tissue in a similar manner to dietary EPA. This provides
evidence that SDA may provide an alternative to EPA for increasing tissue levels
of EPA and DPA, but not DHA.
Flow cytometry analysis of neutrophils following 20h incubation in either
presence or absence of endotoxin indicated that diet did not significantly affect
constitutive or endotoxin-mediated neutrophil survival when fed at current levels.
There was a non-significant trend towards an increase in both constitutive
viability and endotoxin mediated cell survival (p=0.069) in both SDA and EPA fed
animals as compared with control animals that were fed OA. While these results
do not fully explain the role that EPA or SDA play in reducing neutrophil influx
during ARDS, they do provide evidence that it is not through an increase of
neutrophil apoptosis or an attenuation of the neutrophil response to endotoxin.
These findings may indicate the importance of dietary EPA for maintaining host
immune response, while providing beneficial effects in regards to inflammation.
Because of similar action between dietary EPA and SDA these results might also
provide further proof as to the potential for dietary SDA to be used as an
alternative for dietary EPA.
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Introduction
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I. Introduction
Many studies have implicated the importance of the omega 6 (n-6) and
omega 3 (n-3) families of fatty acids in their ability to affect a number of
pathophysiological conditions. Both families of PUFAs have exhibited the ability
to affect a variety of disease states such as, arthritis, coronary artery disease,
cancer and acute lung injury (ALI)[1-5]. There have been several studies that
implicate the role of PUFAs, especially members of the n-6 family, as regulatory
factors for programmed cell death, or apoptosis. This may be particularly
important in inflammatory diseases where the products of fatty acid metabolism,
the eicosanoids, have been shown to activate inflammatory cells such as
neutrophils[6] and increase their lifespan[7].
Neutrophils are the first line of defense in the response to bacterial infection.
These immune cells are equipped with receptor sites that can detect components
of bacteria such as endotoxin, which has been shown to attract and activate
neutrophils[8]. Neutrophil activation by endotoxin has a wide variety of effects
including; an increase in cell lifespan, the release of cytotoxic compounds, and
the increased synthesis of eicosanoid products. The accumulation of activated
neutrophils in the lung is an important feature in the development of ARDS[9].
Excessive neutrophil recruitment, activation, and release of their cytotoxic
granules can lead to severe tissue damage in the lung. Neutrophil mediated
tissue damage results in fluid accumulation and decreased gas exchange. This
damage often results in the transformation of the lung into a non-compliant, end
stage organ. Effective clearance of neutrophils from the lung while containing
granule release is vital in the resolution of ARDS. This clearance is dependent
on neutrophil apoptosis and the recognition of apoptotic bodies by resident
macrophages[9-11].
Eicosanoids formed from the n-6 fatty acid arachidonic acid (AA, 20:4 n-6)
are potent chemoattractants of neutrophils, and have also been correlated with
an observed increase in neutrophil lifespan[12]. AA is found in abundance in
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terrestrial food sources and is readily stored in the phospholipid portion of the cell
membrane. The products of AA metabolism are the potent pro-inflammatory
series-4 leukotrienes and the series-2 prostaglandins. The leukotrienes,
particularly leukotriene B4, has been the focus of interest in incidence of
inflammatory diseases and adult respiratory distress syndrome (ARDS)[4]
because of its ability to attract neutrophils and alter their lifespan.
Conversely, there has been much data supporting dietary intervention with
members of the n-3 family of PUFAs, such as eicosapentaenoic acid (EPA, 20:5
n-3) or docosahexaenoic acid (DHA, 22:6 n-3), both of which are found primarily
in fish oil, having suppressive effects on inflammation and attenuating tissue
damage in conditions such as ARDS. This effect is attributed to a reduction of
membrane phospholipid AA, and the products of EPA metabolism, e.g. the
series-3 prostaglandins and the series-5 leukotrienes, which are on a scale of 30
fold less active than their n-6 derived cousins[13]. The ability of EPA to alter the
concentrations and types of mediators present in an inflammatory response is
apparent in several studies involving septic shock and ARDS[4;14;15] . Clinical
trials have shown that ARDS patients receiving nutritional support with a high fat
low carbohydrate diet containing fish oil as a major contributor of calories had
significantly improved outcomes as compared with those given a traditional corn
oil based nutritional formula. These effects were correlated with lower LTB4
concentration and a decrease in the number of neutrophils present in
bronchoalveolar lavage (BAL) fluid[15].
The effects of n-3 fatty acids in supportive therapy and disease prevention
have led to recommendations from the American Heart Association for an
increase in consumption of fatty fish and fish oil[16]. Unfortunately, due to a limit
on natural fish stocks, new dangers associated with fish consumption due to
environmental pollutants, and a resistance to the incorporation of fish into the
established western diet these recommendations have been left largely
unmet[17]. This has driven a new interest in identifying and developing
alternative sources of n-3 fatty acids, particularly those that would increase tissue
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levels of EPA efficiently when consumed at moderate levels. Recent
development of genetically modified canola seeds that produce stearidonic acid
(SDA, 18:4 n-3)[18] appear to be promising for this purpose.
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II. Rationale and Significance of Study
It has been suggested that critically ill patients fed nutritional formulas
containing high levels of n-6 fatty acids should be avoided, as excessive
release of n-6 metabolites, particularly those derived from AA, may lead to a
hyper-inflammatory condition that has been linked to the development of
systemic inflammatory response syndrome and ARDS[4;19]. Dietary AA has
been shown to increase membrane phospholipid content of AA in several
tissues and cell types. Further, increased membrane phospholipid AA has
been associated with an increased production of pro-inflammatory
eicosanoids from stimulated peritoneal cells (i.e., macrophages, mast cells,
neutrophils)[20]. During conditions such as ARDS, combined endogenous
and exogenous factors such as cytokines and bacterial endotoxin stimulate
cPLA2 mediated AA cleavage from cell membrane phospholipids, resulting in
an up-regulation of synthesis and extracellular release of products of
cyclooxygenase (COX) and lipoxygenase (LO) metabolism from immune
cells[11]. Products of COX and LO metabolism of AA have been shown to
be potent chemoattractants and activators of inflammatory cells[21;22]. In
particular, leukotriene B4, a product of LO metabolism of AA, has been
implicated as a neutrophil attractant and anti-apoptotic factor[12].
Neutrophils play a critical role in inflammation and tissue damage
associated with inflammatory diseases such as ARDS[11]. Alternatively, the
use of n-3 PUFAs, such as EPA from fish oil, has long been recognized as
being beneficial because of the ability of EPA to decrease AA accumulation in
circulating blood and tissue[23;24].

Incorporation of EPA at the expense of

AA has been associated with a decrease in pro-inflammatory eicosanoid
synthesis[25]. Feeding diets that contain n-3 fatty acids from fish oil have
also been associated with an attenuation of symptoms of sepsis and ARDS in
humans and animal models[4;26].
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The effect of n-3 fatty acids on altering the products of eicosanoid
metabolism has been shown to significantly improve patient conditions in a
number of disease states of the lung[27]. Studies have shown that LTB4 is an
active mediator for neutrophil recruitment during pleural cavity inflammation,
as well as in inflammatory lung diseases[28;29]. Work from our laboratory
has demonstrated a reduction in levels of pro-inflammatory eicosanoid
products as well as a decrease in neutrophil accumulation in bronchoalveolar
lavage (BAL) fluid of ARDS patients fed enteral nutrition formulas containing
n-3 fatty acids from fish oil[14;30]. However, these studies did not examine
whether reduced neutrophil counts were due to an increase in apoptosis, or
through a reduction of neutrophil chemotaxis. To address this question our
laboratory examined the effect that coincubation with EPA would have on the
lifespan of the promyelocytic human leukemia cell line, HL-60[31]. These
studies found that direct treatment of HL-60 cells with EPA could significantly
reduce cell viability through an increase in apoptosis. Using various inhibitors
of AA metabolism, the importance of AA-derived eicosanoid products in the
regulation of apoptosis in HL-60 cells was demonstrated[32].
Taken together, data from clinical trials and experiments with the HL-60
cell line suggest that dietary n-3 PUFAs may act by attenuating the increase
in neutrophil lifespan associated with endotoxin activation through an
increase in apoptosis; thereby, decreasing the number of neutrophils
observed in BAL fluid of patients with ARDS receiving nutritional treatment
with n-3 PUFAs. Further, the altered products of eicosanoid formation are
responsible for this decrease in lifespan. However, due to limitations and
different findings between immortalized HL-60 cells and neutrophils it is
important that we examine this hypothesis in the neutrophil. The use of
neutrophils from animals pre-fed modified US-17 diets enriched with EPA will
allow us to determine the effect of pre-loading membrane phospholipids with
EPA has on lifespan in either inactivated basal, or endotoxin activated
neutrophils.
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Many studies have suggested that the addition of n-3 fatty acids to the diet
can have numerous beneficial effects[33]. Although these findings and
subsequent recommendations from the American Heart Association have,
until recently, been impractical because of supply and safety concerns of
natural fish stocks[16;17]. The development of canola plants that accumulate
SDA in their seeds[18] might provide a twofold benefit. First, this may offer a
practical strategy for providing a dietary source of EPA without the supply
limits and safety concerns that surround an increased intake of dietary fish oil.
Second, in situations where it is desirable to provide dietary EPA as
therapeutic support for critical care patients, an enteral formula containing
modified canola oil would most certainly be a cost effective alternative as
compared with diets relying on EPA derived from fish oil. This strategy is still
in question, as previous work with another n-3 fatty acid, α-linolenic acid
(ALA, 18:3 n-3), has indicated that the enzymatic fatty acid desaturation and
elongation pathway responsible for the conversion to longer chain PUFAs
might be too inefficient for the use of precursor fatty acids to increase tissue
EPA content[18;34;35] . However, dietary SDA is the metabolic product of
the ∆-6 desaturase enzyme action on ALA. It has been long held that ∆-6
desaturase is the rate limiting step in fatty acid metabolism; thus, the
efficiency of conversion and storage of SDA as EPA may be greater than that
observed in experiments that fed ALA[18].
There have been relatively few studies that compare feeding diets
enriched with SDA to diets rich in EPA, and most of the studies involving
these fatty acids have been designed using oil blends that contain high levels
of EPA and SDA[36-38]. In light of this, comparing the effect of feeding diets
containing purified SDA ethyl esters on altering tissue phospholipid fatty acid
profiles with the effects observed when feeding a diet containing purified EPA
ethyl esters may provide valuable insight into the potential for SDA to be used
as a precursor molecule for increasing EPA levels in membrane
phospholipids. Further, this experimental design will allow us to compare the
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effects of purified SDA ethyl esters with that of purified EPA ethyl esters on
neutrophil lifespan and apoptosis rates during endotoxin activation.
The hypotheses of this study are twofold; first, that diets supplemented
with SDA ethyl ester may provide a means to increase EPA content in liver
phospholipids, and that this increase will be similar to those observed in
animals fed a diet containing EPA. Second, that dietary supplementation
with SDA or EPA will impact the regulation of constitutive and endotoxininduced survival in neutrophils by influencing the rate of apoptosis in both cell
states.
The current study design will utilize glycogen-elicited neutrophils from
male Long-Evans rats that were pre-fed diets enriched with purified EPA or
SDA ethyl esters. Harvested neutrophils will be incubated overnight in either
the presence or absence of bacterial endotoxin to induce an activated cell
state similar to that seen in models of sepsis or ARDS. Following incubation,
flow cytometry will be used to examine the effect of diet on altering neutrophil
lifespan in both an inactive and LPS activated cell state. Gas
chromatography analysis of liver tissue will be utilized to provide information
on the incorporation of EPA and SDA from dietary sources into membrane
phospholipids.
The significant features of this study are many fold; first, feeding purified
EPA ethyl ester will allow us to confirm and examine the incorporation of EPA
into membrane phospholipids. Using gas chromatography we can examine
whether EPA ethyl ester provided in the diet is directly incorporated into
membrane phospholipids, and if it is enzymatically altered and stored as other
n-3 fatty acids. This design will also allow us to confirm previous studies that
indicate EPA content in membrane phospholipids is increased at the expense
of AA. Second, simultaneous feeding of diets containing purified SDA ethyl
ester will allow us to examine the potential of dietary supplementation with
SDA as an alternative to diets enriched with EPA for modifying membrane
phospholipid fatty acids. Third, pre-feeding animals diets containing EPA
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and SDA also allows us to examine the effect of fatty acid incorporation and
membrane pre-loading with respect to neutrophil lifespan and apoptosis. Ex
vivo treatment of neutrophils allows us to examine the effect diet may have on
lifespan in both the inactive and endotoxin activated conditions in cells from
individual animals. This design utilizes both endotoxin treated and untreated
cells from the same animal; thereby, allowing each animal to act as its own
control, minimizing the potential for genetic variability on the effect of diet or
endotoxin treatment.
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III. Objectives
Objective 1: To examine whether diets supplemented with SDA ethyl ester
can be used as a precursor to increase EPA content in liver phospholipids
and to determine the effectiveness of SDA in increasing tissue EPA and
reducing tissue AA content in rat liver.
Objective 2: To evaluate the effect of dietary EPA and SDA on the regulation
of basal and endotoxin-induced neutrophil survival using glycogen-elicited
peritoneal neutrophils from the rat.
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I. Essential Fatty Acids and Eicosanoid Synthesis
Essential Fatty Acids:
In 1929 Burr and Burr discovered that the exclusion of certain fatty acids from the
diets of laboratory rats would produce a disease state. Animals developed scaly
skin, swollen and scaly tails, and hair loss from the face, tail, and throat[1].
These fatty acids were later termed “essential” because higher mammals lack the
enzymatic pathways responsible for their synthesis de novo, and they must be
obtained from the diet[2]. Essential fatty acids are polyunsaturated fatty acids
(PUFAs), meaning that they are 18 carbons or more in length and have
numerous double bond positions throughout their carbon backbone. The
positioning of the first double bond proximate to the methyl end of the fatty acid is
used as a reference to classify essential PUFAs as members of either the
omega-6 (n-6) or omega-3 (n-3) family of fatty acids[3]. The essential nature of
these PUFAs is due to the lack of enzymes responsible for desaturation past the
ninth carbon of the fatty acid chain from the carboxylic end of the molecule.
Further, it has been shown that fatty acids from these families are not
interchangeable[4].
The parent fatty acids of the n-6 and the n-3 families of fatty acids are
linoleic (LA; 18:2n-6) and α−linolenic (ALA; 18:3n-3) acids, respectively. In the
strictest sense of the term, only the parent compounds of the n-6 and n-3 are
truly essential, as an enzyme system exists to elongate and desaturate the 18
carbon PUFAs to form the other members of the essential fatty acid family[5].
Although, as previously mentioned these fatty acid families are not
interchangeable, they are metabolized by the same enzymatic elongation and
desaturation pathways[3] (Figure 2.1). LA is desaturated and elongated to form
arachidonic acid (AA; 20:4n-6), which is considered to be the bioactive n-6 fatty
acid for the production of inflammatory compounds[6]. Along the same lines ALA
can be converted to stearidonic acid (SDA; 18:4n-3) and then to
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Figure 2.1 Pathways of Fatty Acid Synthesis.
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eicosapentaenoic acid (EPA; 20:5n-3), which is the n-3 fatty acid counterpart to
AA, and has been shown to attenuate the formation of proinflammatory products
attributed to AA metabolism[7]. For this discussion we will focus on AA, SDA,
and EPA. The main dietary source of AA is from consumption of animal
products, although a small amount is synthesized by metabolism of LA from plant
sources[8]. The beneficial effects of fish oil have been mainly attributed to the
long chain PUFAs EPA and DHA. Typically, DHA nor EPA are not produced in
terrestrial organisms, but found primarily in marine sources, such as cold water
fish and fish oil[9;10]. SDA has been found in low abundance in certain seed
oils, such as from Echium plantaginium, and recently has been produced in
genetically modified canola plants[10;11]. Lipid derived eicosanoid products of
AA metabolism have been ascribed a vital role in the development of
inflammation, and have been implicated in the pathogenesis of sepsis, systemic
inflammatory response syndrome, acute lung injury and acute respiratory
distress syndrome[8;12].
Because of safety concerns associated with fish consumption, cost, and a
limit on natural fish stocks the inclusion of fish into the western diet on a large
scale is problematic and impractical[13]. Thus, there has been an urgent need
for the location of alternative sources by which to provide n-3 PUFAs to the diet.
Initially, the potential of ALA provided by diet to increase tissue levels of EPA and
DHA was examined. These studies found that this reaction is too inefficient for
dietary ALA to significantly alter the levels of n-3 fatty acids found in tissue
membrane phospholipids[10]. The conversion of ALA to EPA is a three step
enzymatic process, in which ALA is first desaturated by the ∆6 desaturase
enzyme to SDA and then elongated by 2 carbons to form EPA. The ∆6
desaturase enzyme has been shown to be the rate limiting step in the conversion
of ALA to EPA[14]. Stearidonic acid is the product of ∆6 desaturase activity on
ALA, and has gained interest as a precursor fatty acid for increasing n-3 PUFA
content in tissue phospholipids, as it bypasses the rate limiting step in fatty acid
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conversion to EPA and has been shown in some models to be more efficient at
increasing tissue EPA as compared with ALA provided by diet[15].
Eicosanoids are biologically active products of either enzymatic or nonenzymatic oxidation of 20 carbon chain length PUFAs[6]. Synthesis of
eicosanoid products begins with the cleavage of either AA or EPA from their
storage position in the sn2 position of the cell membrane phospholipids. This
cleavage is carried out by cystolic phospholipase A2 (cPLA2), which is a member
of a broad family of enzymes that are characterized by their ability to hydrolyze
the center, sn2, position of substrate phospholipids[16]. Activation of cPLA2 is a
calcium dependant process, and yields a free fatty acid that can then be ferried
to the nuclear membrane of the cell for further metabolism by cyclooxygenase,
lipoxygenase, or cytochrome p450. For this discussion we will focus on the
products of the lipoxygenase and cyclooxygenase enzyme pathways.
Cyclooxygenase Activity:
Prostaglandin endoperoxidase H synthases (PGHS; cyclooxygenase; COX)
catalyze the committed step in the formation of prostanoid products from the 20
carbon fatty acids.

There are two isoforms of COX enzymes, COX1 and COX2,

both of which share approximately 60-65% sequence homology. All of the amino
acids deemed necessary for COX1 function are present in the COX2
enzyme[17]. COX1 is a 576 amino acid length protein, while COX2 is a 587
amino acid protein. COX1 is considered to be constitutively active, and is
involved in the production of housekeeper molecules, while COX2 is an inducible
enzyme and is mainly activated in response to inflammatory stimulus which
results in an enhanced prostaglandin production[18;19]. COX2 possesses an 18
amino acid sequence, inserted 6 residues in from the C-terminus that is not
present on the COX1 enzyme[20]. Both isoforms of COX enzymes are located
on the luminal face of the endoplasmic reticulum, and on both the inner and outer
faces of the nuclear envelope. COX2 is more concentrated on the inner surface
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of the nuclear envelope, possibly to facilitate the role of its products as nuclear
regulators.
COX1 and COX2 utilize a two-step conversion process to metabolize AA
to prostaglandin H2 (PGH2). This conversion is carried out by two discreet active
sites on the enzyme. First, AA is combined with two molecules of oxygen in a
bis-oxygenase reaction to form prostaglandin G2 (PGG2) in an enzymatic pocket
on the hydrophilic surface of the enzyme. PGG2 is then transported to a second
pocket in the hydrophobic core of the COX1 enzyme where it is reduced to form
PGH2 through a peroxidase reaction that removes two electrons from PGG2[17].
PGH2 from COX1 is then released into the cytoplasm of cells to be converted to
an active prostaglandin by other enzymes. Whereas PGH2 formed by the COX2
enzyme most likely is transported to the nucleus[17].
Metabolism of AA by COX1 or COX2 results in the formation of the 2series prostaglandins, where the subscript 2 denotes the number of double
bonds in the molecule. Both COX1 and COX2 are capable of metabolizing EPA
to prostaglandin products, although at a greatly reduced rate[21]. The additional
double bond found in EPA as compared with AA results in the formation of
prostaglandin products containing 3 double bonds along the carbon backbone of
the molecule. These products are denoted by the subscript 3 (i.e., PGH3), and
are referred to as the 3-series prostaglandins.
Once released into the cell cytoplasm, the PGH products of COX activity
can be metabolized by a number of enzymes to form prostaglandin products
which are actively involved in cell signaling. These include PGE2, PGD2, PGF2α,
PGI2, and thromboxanes. PGD2 can be transformed by two steps of dehydration
and one step of double bond migration to form ∆12-PGJ2 and 15-deoxy-∆12,14PGJ2, which have been shown to induce apoptosis in neutrophils[22]. The
reactions involved in transforming AA to cell signaling products are carried out by
discreet heterogenous enzymes and non-enzymatic reactions. The
prostaglandin products of AA metabolism have been linked with the pain,
redness, and swelling associated with inflammation[19]. PGE2 induces fever,
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increases vascular permeability, vasodilation, as well as pain and edema
enhancement[23]. However, on the cellular level PGE2 has also been shown to
exhibit anti-inflammatory actions such as reducing lymphocyte proliferation, and
suppressing the production of pro-inflammatory cytokines such as TNF-α, IL-1,
and IL-6[18]. PGI2, or prostacyclin, exerts potent anti-thrombic and vasodilatory
effects through interaction with vascular smooth muscle tissue and platelets[24].
Thromboxane A2 (TXA2) is produced by activated platelets and has strong
thrombogenic, vasoconstrictive, and bronchoconstrictive properties[25].
As mentioned above, EPA can be metabolized by the COX enzymes,
although at a reduced rate as compared with AA to form the 3-series
prostaglandins. During prostaglandin formation there is further competition
(aside from competing for position in the cell membrane) between the two
classes of PUFA for COX activity which results in a decrease in the formation of
AA derived COX products. Many of the products of EPA metabolism exhibit a
reduced biological activity[26]. For example thromboxane A3, a product of EPA
metabolism, is a weak vasoconstrictor and weak platelet aggregator as
compared with TXA2 derived from AA[23]. The biological activities of PGE3 are
also muted as compared with PGE2[27]. Besides the decreased biological
activity of PGE3, EPA has also been demonstrated to decrease the production of
PGE2[28]. There are exceptions, however, such as the case of the EPA
prostacyclin product, PGI3, which is as biologically active as PGI2 as a
vasodilator and platelet aggregator[23].
Prostaglandins exhibit their effects, with few exceptions, via a family of
prostaglandin receptors. Each of the receptors has a high binding affinity for a
specific prostaglandin, although there can be considerable cross reactivity
among the receptors and ligands. The prostaglandin receptors are seven
transmembrane domain receptors, belonging to the heterodimeric G-proteincoupled, rhodopsin-type superfamily[29]. The nomenclature of receptors is
based on the ligand that they bind. For example, DP binds to PGD, TP binds to
thromboxanes, IP binds to PGI, etc.. Within this superfamily of receptors the
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branch dedicated to PGE binding is composed of four members (EP1, EP2, EP3,
EP4), constituting a complete receptor sub-family[25]. Each prostaglandin
receptor can be classified in one of three categories, based on the G-protein
homodimer activated, and the cell response. These categories are the relaxant
receptors, contractile receptors, and the adenylate cyclase inhibitors. The
relaxant receptors consist of IP, EP2, EP4, and DP. Activation of these receptors
stimulate cAMP production through adenylate cyclase activation[29-31]. The
contractile receptors are TP, EP1, and FP and are associated with increasing
intracellular calcium levels[29;32]. EP3 is the sole member of the adenylate
cyclase inhibitor family[29]. Exceptions to the prostaglandin ligand-receptor motif
are the PGJ products of PGD metabolism. These prostaglandins have no
specific cell surface receptors, instead are actively transported across the cell
membrane[33]. Once inside the cell they can interact with proteins directly via a
cross conjugated dienone unit that can react with thiol nucleophiles, thereby
altering protein function[22].
Lipoxygenase Activity:
The lipoxygenase enzymes are a class of non-heme iron containing enzymes
that catalyze the incorporation of molecular oxygen into PUFAs[25]. This
reaction is positionally selective, which is reflected by lipoxygenase
nomenclature, as the enzymes are named after the carbon atom that they
preferentially attack. Based on this system of classification the lipoxygenase
enzymes are divided into three categories; the 5-, 12-, and 15-, lipoxygenases,
respectively[25].
12-lipoxygenase (12-LO) was the first lipoxygenase enzyme to be
discovered in the mammalian system, and has been found in the cytosolic
fraction of a number of cell types. There are reports that state that 12-LO is
translocated to the cell membrane in a calcium dependent mechanism, and that
this translocation deactivates the enzyme[34-36]. 12-LO is primarily responsible
for the synthesis of 12-hydroperoxyeicostetraenoic acid (12(S)-HPETE) from AA,
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which is the parent compound of the hepoxilins and trioxilin[34]. Hepoxilins are
monohydroxy-epoxy derivatives of PUFAs and consists of two known derivatives,
hepoxilin-A3 and –B3. Hepoxilins can be hydrolyzed to form another metabolite
group called trioxilins, which also has two derivatives, (trioxilin –A3 and B3)
depending on the precursor molecule[34]. 12-LO can also metabolize EPA to 12hydroperoxyeicospentaenoic acid (12(S)-HPEPE). Although the biological
activities of the 12-LO PUFA metabolites are much less well defined than those
of the prostaglandins or the biologically active leukotriene products of 5lipoxygenase activity, they have been shown to be involved in a number of
processes, including the increase of intracellular calcium in neutrophils by
hepoxilins A3[34;37]. More work is needed to determine the effects of 12-LO
products during pathological conditions.
15-lipoxygenase (15-LO) is another cytosolic protein member of the
lipoxygenase family, which catalyzes the oxygenation of AA to 15hydroperoxyeicosatetraenoic acid (15 (S)-HPETE), and similarly transforms EPA
to 15-hydroperoxyeicosapentaenoic acid (15 (S)-HPEPE)[25;38]. 15-LO was first
discovered in rabbit reticulocytes, and later two separate isoforms were identified
in humans[39]. These isoforms are 15-LOa and 15-LOb, and are classified
based on tissue distribution and substrate specificity. 15-LOa was the same
protein that was first purified from rabbit reticulocytes, and is widely distributed in
human eosinophils, bronchial epithelial cells, peripheral blood leukocytes, liver,
kidney, spleen, thymus, testis, skeletal muscle, heart, and brain. In contrast,
15LOb has only been isolated in the prostate, skin, lung, and cornea[39]. 15-LO
is also an active enzyme for shorter chain 18 carbon fatty acids, such as LA or
ALA. A second feature unique to15-LO is that it can also oxygenate metabolites
that are esterified to phospholipids, independently of phospholipase activity[25].
It has been shown that each 15-LO isoform preferentially utilizes different
substrates. 15-LOa preferentially metabolizes LA to 13(s)hydroperoxyoctadecadienoic acid (13(S)-HODE), and metabolizes AA to 15(S)HETE. In contrast, 15-LOb converts AA to 15(S)-HETE, but is a poor enzyme for
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LA[39]. Products of 15-LO metabolism have been shown to possess various
biological properties in a number of cell types. 15(S)-HETE has been shown to
modulate pain response in rat skin, alters the growth of rat liver epithelial cells,
regulates the secretion of prolactin in fibroblasts, induce a hypersensitivity to the
β-adrenergic response in rat cardiomyocytes, and in erythroleukemia cells 15HETE has been shown to regulate protein phosphorylation and cell
proliferation[40]. 13-HODE has been linked with inducing histamine
hypersensitivity in guinea pig airways, and modulating the EGF signaling tyrosine
phosphorylation in fibroblast cultures[25;40]. There have been some studies that
imply a particular importance for 15-LO in the lung, at least in epithelial cells.
Several studies have demonstrated that tracheal and bronchial epithelial cells
produce 15-LO products, and that the removal of the epithelial layer results in a
reduction of 15-LO activity[38;41;42]. In other studies15-HETE has been shown
to induce mucus and chloride secretion in human lung epithelium, and mucus
secretion and inflammation in canine airway epithelium[40]. The involvement of
15-LO in the inflammatory response has been illustrated in several studies in
which it has been shown to reduce 5-lipoxygenase activity, reduce leukotriene
mediated chemotaxis, and reduce superoxide anion generation in
neutrophils[39]. In one of the most recent studies, the 15-LO product, 15-HETE
was shown to have a regulatory effect on the LPS-induced production of tumor
necrosis factor-α in human monocytic cell lines. 15-HETE exhibited this effect by
degrading TNF-α mRNA[43].
Perhaps the most well studied of the lipoxygenase enzymes is 5lipoxygenase (5-LO). This enzyme pathway is responsible for the production of
the leukotrienes, which have been shown to have a wide range of effects on
inflammation and innate immunity[44]. Intracellularly, 5-LO is located in the
cytosolic fraction of resting leukocytes and upon activation associates with the
nuclear envelope[45]. 5-LO requires an interaction with both phospholipase A2
and 5-LO activating protein (FLAP)[46]. Following cleavage of AA or EPA from
the cell membrane by PLA2, FLAP along with PLA2 and AA translocate to the
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nuclear envelope to the site of 5-LO[45]. The translocation of all these
participants of 5-LO enzyme activity are calcium dependant, based on studies
using the calcium ionophore, A23187[47-49]. Following nuclear assembly of the
5-LO complex the enzyme can catalyze the synthesis of the leukotrienes from AA
or EPA. Metabolism of AA results in the formation of the 4-series leukotrienes,
while EPA metabolism results in the formation of the 5-series leukotrienes[50].
5-LO first converts AA to 5-(S)-hydroperoxyeicosatetraenoic acid (5-HPETE),
and then converts 5-HPETE to leukotriene A4, which is the parent compound for
leukotriene synthesis[51]. LTA4 is an unstable epoxide that can either be
enzymatically conjugated with reduced glutathione to form leukotriene C4 (LTC4),
or hydrolyzed to leukotriene B4 by LTA4 hydrolase[52]. LTC4 is the parent
compound of the cysteinyl leukotrienes, which were originally described as the
slow reacting substances of anaphylaxis. LTC4 can be metabolized to leukotriene D4 (LTD4) by elimination of glutamic acid by γ-glutamyl transpeptidase.
LTD4 can be hydrolyzed by a dipeptidase to leukotriene E4, removing the
remaining peptide bond, forming LTE4[53].
The cysteinyl leukotrienes are produced mainly by activated eosinophils,
basophils, mast cells, and macrophages. They were first identified by their
smooth muscle contracting properties, and were associated with asthma and the
allergic response[54]. Although there have been some recent papers that
implicate the cysteinyl leukotrienes with the release of pro-inflammatory
cytokines, an increase in microvascular permeability, and the induction of
pulmonary fibrosis[55].
LTB4 is a leukotriene of major importance in regards to immune function
and the inflammatory response. Structurally LTB4 is similar to the cysteinyl
leukotrienes, having a 20-carbon backbone, and multiple double bonds, although
lacking the peptide side chain, but possessing an additional hydroxyl group at C12[56]. LTB4 is produced mainly by immune cells such as alveolar macrophages,
and acts as a potent chemoattractant and stimulator of neutrophils to sites of
infection and inflammation[44]. LTB4 has been shown to promote neutrophil
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chemotaxis, and to up-regulate the interaction between activated neutrophils and
vascular endothelial cells[19]. LTB4 is a stimulator of lysosomal enzyme and
superoxide anion release in neutrophils. LTB4 also increases the generation of
the chemotactic agent interleukin-8 by neutrophils[56]. LTB4 has also been
shown to mediate survival in neutrophils by decreasing apoptosis[19]. There
have also been reports that LTB4-mediated cell survival is associated with the
survival pathway observed when neutrophils are exposed to bacterial endotoxin,
although this is debated[57;58]. LTB4 is an important mediator for the immune
system, especially in the lung, where alveolar macrophages have been shown to
exhibit an enhanced release of LTB4 as compared with other monocytes,
indicating the role of LTB4 as an early response mediator of innate immunity[41].
As previously mentioned, lipoxygenase enzymes can form EPA derived 5-series
leukotriene products. This is the case with LTB5, which is structurally related to
LTB4, but is less biologically active[59].
Like the products of the cyclooxygenase pathway, both LTB4 and the
cysteinyl leukotrienes exhibit their effects through interactions with members of
the G-protein-seven-transmembrane receptor family. LTB ligands interact with
two surface receptors; BLT1 and BLT2. These receptors are present in high
numbers on inflammatory cells and vascular endothelial cells. Coupling of LTB to
either receptor induces an increase in intracellular calcium levels as well as
chemotactic responses in neutrophils[60]. The cysteinyl leukotrienes interact
with two receptors as well. These are CysLT1 and CysLT2 receptors. These
receptors have been found in bronchial tissue, and expressed on CD45+
leukocytes, macrophages, mast cells, neutrophils, and eosinophils in
humans[55].
Another class of lipoxygenase products is the lipoxin family. The name
lipoxin is an acronym for lipoxygenase interaction products. These eicosanoids
are products of multiple lipoxygenase enzyme reactions that are carried out in
cell-to-cell interactions[25]. The lipoxins were first identified by Serhan et al[61]
from purified fractions of leukocyte suspensions that were coincubated with 15-
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HETE and calcium ionophore A23187. Lipoxygenase formation occurs by one of
three pathways (two of which occur naturally and one of which involves the nonsteroidal anti-inflammatory drug, aspirin) depending on the cells involved in
interactions at the time of formation[62]. The earliest pathway to be described
was for the formation of lipoxin A4 (LXA4) [63;64]. This formation involves the
interaction between neutrophils and platelets. 5-LO activity in the neutrophil
produces LTA4, which is released from the neutrophil and taken up by the
platelets. 12-LO activity inside of the platelets then transforms LTA4 to LXA4. A
second pathway involves the interaction between 15(S)-HPETE or 15(S)-HETE
formed by vascular endothelial cells. During activation neutrophils begin to roll
along vascular endothelial cells in response to chemotactic stimuli, during this
interaction they can pick up the 15-LO products from the endothelial cells. These
products are subjected to metabolism by 5-LO in the neutrophil and forms an
unstable intermediate, 5,6-epoxytetraene (5,6-ETE). 5,6-ETE is rapidly
converted by epoxide hydrolases to three products, LXA4, LXB4, or 7-cis,11trans-lipoxinA4[25]. The final pathway for lipoxin formation involves the
acetlyation of COX-2 by aspirin. This shifts the activity of the COX-2 enzyme in
monocytes to one that mimics a lipoxygenase enzyme, forming the product
15(R)-HETE. 15(R)-HETE is structurally similar to 15(S)-HETE formed by 15-LO
with the exception that the 15-C in the chain has its alcohol group in the R
conformation. Once released, 15(R)-HETE can be taken up by neutrophils and
metabolized by 5-LO, forming 15-epiLXA4, or 15-epiLXB4[65].
The pharmacological activities of the lipoxins are involved heavily in the
resolution of inflammation. They have been shown to inhibit neutrophil and
eosinophils trafficking by reducing sensitivity to LTB4 and PAF, as well as to
stimulate the macrophage mediated clearance of apoptotic neutrophils[66].
Lipoxins exert their influence in two ways. First there is a lipoxin-specific
recognition site that has been localized on human neutrophils. This is thought to
be a member of the G-protein-coupled receptor superfamily, although the
downstream signaling has yet to be elucidated. Also, lipoxins are competitive
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inhibitors of cysteinyl leukotriene receptors[62]. Substitution of AA with EPA
leads to the formation of the 5-series lipoxins, which have been shown to be
equally as active as signaling molecules as their AA derived counterparts[67].
Benefits of EPA and SDA:
As mentioned before, the addition of SDA to the diet may have beneficial effects
on inflammatory mediator production because of its potential to be elongated to
EPA[14;68]. SDA has also been shown to possess inhibitory effects on the
oxygenation of AA to eicosanoid products[69]. This effect was later
demonstrated to be due to an inhibition of ∆5-desaturase activity[70]. The
inclusion of EPA into diet or nutritional formulas has been shown to have potent
anti-inflammatory effects in vivo[71-73]. Ex vivo, dietary EPA has been shown to
reduce the synthesis of interleukin-1 and tumor necrosis factor-α by activated
monocytes[74]. EPA has been shown to reduce the formation of PGD2 by
inhibiting COX-2[75]. Besides inhibitory effects, EPA can be used as a substitute
for AA in the formation of eicosanoids[8]. This substitution leads to the formation
of products that are much less bioactive than their AA derived cousins. One
example of this is LTB5 which is much less active than LTB4[76].
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II.

Apoptosis

Mechanisms of Apoptosis:
Apoptosis is an active process by which cells undergo a controlled breakdown of
systems and molecules, leading to programmed death. Apoptosis was first
observed in the late 19th century by C. Vogt during morphological examinations
of amphibian cells. This process was lost and rediscovered over the years in a
variety of cell types. The term apoptosis was coined in a paper by Kerr et al in
order to describe non-necrotic cell death[77]. The apoptotic process begins in
response to a stimulus, which triggers an energy requiring pathway leading to
destruction of the cell by a characteristic set of reactions[78]. Necrosis is a
passive process, typically in response to some insult to the cell leading to a loss
of membrane integrity. The fate of the necrotic cell is fluid influx, swelling, and
eventually rupture, emptying the contents of the cell into the environment[77].
The apoptotic pathway, on the other hand, leads to the inactivation and death of
the cell without loss of the external membrane. As previously mentioned,
signaling molecules that are expressed on the cell membrane during the
apoptotic process target these cells for removal by phagocytic cells before the
loss of membrane integrity can occur. Another important difference between
apoptosis and necrosis is mitochondrial involvement. During apoptosis several
studies have shown that the mitochondria exhibit a loss in the mitochondrial
membrane potential (∆Ψm) which coincides with the appearance of the
permeability transition pore (PT). This loss of mitochondrial membrane potential
allows small pro-apoptotic proteins to leak into the cytosol, which amplifies and
perpetuates the apoptotic signal[79]. The timing of mitochondrial participation
has been used to elucidate the existence of two separate signaling pathways for
apoptosis, which will be discussed further. Although apoptosis is an important
process for the normal physiological functioning in numerous systems, this
discussion will focus on the pathways and factors associated with apoptosis in
the neutrophil and the inflammatory process.
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Regardless of cell type, apoptosis is an ordered process which consists
of 3 phases; initiation, execution, and termination. Initiation can occur by a
number of intrinsic and extrinsic factors. Several examples of apoptotic inductors
are growth factor withdrawal, ultraviolet or gamma radiation exposure,
chemotherapeutics, or activation of membrane expressed cell death
receptors[77]. Initiation by activation of cell death receptors is mediated through
members of the tumor necrosis factor/ nerve growth factor (TNF/NGF)
superfamily of receptors. These receptors all share a cysteine-rich extracellular
domain, and a signal transducing intracellular death domain (DD). To date there
have been six cell death receptors identified; TNFR1 (CD120a), CD95 (APO-1,
Fas-1), DR3 (APO-3, LARD, Tramp, WSL-1), TRAIL R-1 (APO-2, DR-4), TRAIL
R-2 ( DR-5, KILLER, TRICK-2), and DR-6. Of these six, CD95 has been most
well characterized. In the CD95 model of apoptotic induction, activation of the
CD95 receptor by CD95 ligand (CD95l) leads to oligomerization of TNF/NGF
receptors, forming an apoptotic signaling complex. Ligation and oligomerization
of these receptors induces recruitment of the intracellular adaptor protein, Fasassociated death domain (FADD), to the cytoplasmic portion of the receptors.
Association of FADD with the DD of the receptor complex sequesters molecules
of pro-caspase 8 to the site, which interacts with other components to form the
death induced signaling complex (DISC)[77;80;81]. Pro-caspase 8 is a member
of an important family of proteases that are responsible for the execution phase
of apoptosis; namely, the caspases. Caspases are a family of intracellular
cysteine proteases with conserved sequence sites for binding and catalysis.
Caspases cleave their substrates following accessible aspartic acid residues,
which is where their name is derived (cysteinyl aspartate specific proteases).
Cleavage of substrates by caspases leads to a cascade of signals that result in
controlled deconstruction of proteins and DNA, making these proteases vital
initiators and effectors of programmed cell death[80;82].
In order to control caspase activity, the molecules are initially produced as
inactivated zymogens, composed of three domains: an N-terminal pro-domain, a

34
p20, and a p10 domain. The active moiety is a heterodimer of the p20/p10
domains, formed by the cleavage of the pro-domain. The sites of cleavage
required for caspase activation are all located following aspartate residues,
making them candidate sites for autolytic cleavage. Aggregation of pro-caspase
8 molecules at the site of DISC formation increases their concentration
sufficiently to allow autolytic activation to occur[83]. The proteolytic activation of
caspase-8 begins a downstream cleavage of substrates, ultimately ending in
apoptosis. The caspase cascade depends on three vital caspase family
members; caspases-3, -6, and -7, which are responsible for cleavage of specific
death substrates. These death substrates include various DNA repair
molecules, ribonucleoproteins, signaling molecules, and structural proteins[77].
In the simplest model of caspase-mediated apoptosis, caspase-8 can be viewed
as an initiator caspase, activated at the DISC, leading to activation of executioner
caspases -3, and -7 which in turn activates caspase -6. This model is termed the
“induced proximity model” of apoptosis[84]. In this model cleavage of caspase -3
occurs prior to loss of the mitochondrial membrane potential, indicating a lack of
dependence on the mitochondria[77].
In a second form of receptor-mediated apoptosis, the role of the
mitochondria is crucial to the apoptotic signal transduction cascade that occurs
between caspase-8 and caspase-3[85]. This form of apoptosis is described in
cell types with low levels of caspase-8 association with DISC. In this model the
mitochondria act as signal amplifiers by releasing pro-apoptotic factors into the
cell[86]. Mitochondrial dependent apoptosis involves interactions of several
apoptotic signal regulating proteins, members of the BCL-2 protein family. These
proteins share four BCL sequence homology regions (BH 1-4) and have either
pro or anti-apoptotic effects. The BCL-2 family of proteins can be broken down
into three archetypes. Type 1 BCL-2 family members contain the BH-4 domain
and are anti-apoptotic. While the Type 2 and 3 BCL-2 family members lack this
BH region and are pro-apoptotic[81]. The anti-apoptotic BCL-2 family members
include BCL-2, BCL-XL, MCL-1, BCL-W, A1, and BOO. The pro-apoptotic BCL-2
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family members consist of two sub-types: Type 2 BCL-2 proteins contain BH
regions 1-3, while type 3 BCL-2 proteins contain the BH-3 homology region only.
The BH-3 region proteins include BAD, BID, BIM, BMF, BIK, BLK, HRK, NOXA,
PUMA, NIX, and BNIP3. While the BH-4 family members have been shown to
have other roles besides apoptosis inhibition, the BH-3 only proteins have been
identified as exclusive cell death promoters[80]. Although the mechanisms are
still being determined, members of the BCL-2 family are thought to interact with
the mitochondrial membrane by formation of pores; the pro-apoptotic BH-3
members promote pore formation, while the BH-4 domain containing family
members inhibit pore formation.

The presence of these pores allows leakage of

several compounds into the cytosol of the cell, including cytochrome-c, which is a
key component in formation of a holoenzyme complex called the
apoptososme[77]. Dimerization of pro- and anti-apoptotic BCL-2 proteins results
in formation of heterodimeric neutral molecules[81]. This model emphasizes the
importance of a balance between pro- and anti-apoptotic family members, as
shift towards the apoptotic proteins would induce a change in mitochondrial
membrane potential, allowing cytochrome-c leakage to occur. Regardless of
mechanism, the role of the BCL-2 proteins can be simplified to the regulation of
mitochondrial components, particularly cytochrome-c, into the cytosol.
In mitochondrial-dependant apoptosis, signal transduction from caspase-8
to caspase-3 requires activation of procaspase-9. As previously mentioned,
activation of procaspase-9 requires formation of the apoptosome[81]. The
apoptosome is a wheel like protein heptamer, made up of seven molecules of
cytosolic protein, Apaf-1, and mitochondrial cytochrome c[87]. Apaf-1 contains a
long C-terminal extension with 13 repeats of a WD40 motif. Apaf-1 also contains
an amino-terminal caspase recruitment domain and nucleotide binding domain.
Under normal circumstances Apaf-1 adapts a compressed conformation, which
prevents oligomerization with other proteins. Cytochrome c released from the
mitochondria binds to the WD40 motif, inducing the protein to adapt an open
conformation. Following this unfolding process, Apaf-1 proteins can heptamerize
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in an ATP dependent reaction to form a “seven spoke wheel” holoenzyme with
the amino-terminal caspase recruitment domain facing the “hub”. This allows
the collection of procaspase-9 enzymes to the hub region of the enzyme.
Dimerization of procaspase-9 leads to the activation of a single monomer of the
subunit[87;88]. The completed apoptosome then activates caspase-3, which in
turn activates other executioner caspases, and induces apoptosis in the same
manner as the induced proximity model.
Morphological Changes of Apoptosis:
Morphological characteristics were first described at great lengths in a 1972
paper by Kerr, Wyllie, and Currie following extensive electron and light
microscopic observations[89]. The hallmark morphological characteristics occur
during the termination phase of apoptosis, following initiation and activation of
signaling molecules. These changes are nuclear condensation, cell shrinkage,
formation of apoptotic bodies, and finally phagocytosis by other cells[90].
Morphologically, the onset of apoptosis begins cell shrinkage and
membrane blebbing. Blebbing is thought to occur through proteolytic cleavage of
structural components of the cell and nuclear membrane (cell death substrates),
such as actin and fodrin cleavage by caspase-3 activated calpain[91]. While
cellular shrinkage is a result of net loss of water from the cell to the extracellular
environment from fusion of the golgi apparatus and endoplasmic reticulum with
the cell membrane, and later the formation of apoptotic bodies[90]. Another very
important change in the cell membrane is expression of phosphatidylserine on
the outer membrane leaflet. Phosphatidylserine (PS) is a protein that is actively
confined to the inner leaflet of the cell membrane during normal circumstances
by the enzyme, aminophospholipid translocase. Relocation of PS to the outer
leaflet of the cell membrane is brought about during the caspase-mediated
cleavage of fodrin, which disrupts cell membrane symmetry and allows the PS
molecule to “flip” to the outer cell membrane[92]. Expression of PS is vital for
recognition and removal of apoptotic cells by macrophages[93].
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Simultaneous to cellular shrinkage and membrane blebbing is a marked
nuclear chromatin condensation. This chromatin condensation results in
formation of compact, crescent shaped masses about the nuclear envelope. The
nucleolus of the cell also undergoes shrinkage and chromatin aggregation.
Eventually the nucleus itself begins to condense and break apart. Nuclear
changes, like those observed in the cytosol, are a result of protease activity.
Chromatin condensation may be a result of the cleavage of lamin-B1, which is
responsible for connecting chromatin to the nuclear matrix. Loss of nuclear
structural integrity is also the result of caspase-mediated lamin-A
degradation[90;91]. Activated caspases are also responsible for DNA cleavage
into 180-200bp double stranded fragments. This cleavage is mediated by DNA
fragment factor (DFF40) and caspase-activated DNase (CAD). Both of these
molecules are constitutively present in an inactive form. Cleavage of their
inhibitor domains by caspase-3 activates their DNase properties[90].
In later stages of apoptosis, cell membranes form elongated extensions.
These extensions eventually break off and the plasma membrane seals to form a
separate membrane around the detached solid cellular material. These products
of budding are termed apoptotic bodies. Apoptotic bodies contain well
preserved, albeit crowded, cellular structures and organelles. These apoptotic
bodies are usually quickly phagocytized by nearby macrophages; however, if
allowed to remain they will degrade in a process that resembles necrosis, which
has been termed secondary necrosis[90;94].
Apoptosis Versus Necrosis:
As previously mentioned, apoptotic cells that are not engulfed by phagocytic cells
eventually degrade into a necrotic-like state. Necrosis is a modality of cell death
that is typically induced by some insult. The process of necrosis is a passive
one. Morphologic changes to the cell involve a loss in plasma membrane
integrity, which allows influx of water and electrolytes. This fluid influx causes a
rapid swelling of the cell leading to rupture of the cell membrane, and loss of cell
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contents to the extracellular environment[90;95]. Necrosis also brings about an
irregular chromatin clumping in the nucleus.
Apoptosis is an energy requiring, orderly process. The process of
apoptosis can be disrupted or altered by deletion or perturbation of pathway
members[81]. Histologically, apoptosis occurs in individual cells, whereas
necrotic cells often occur in clumps of tissue and are often thought of as being
indicative of a pathological condition[95]. Also, apoptotic cells do not induce an
inflammatory reaction, owing to the maintenance of membrane integrity until
clearance, whereas necrotic cells are associated with a spillage of cellular
components that induces an inflammatory reaction[94].
Perhaps the most striking contrast between apoptosis and necrosis is the
lack of surface changes in the cell membrane. The difference between apoptosis
and necrosis membrane changes are best illustrated by the observation that
necrotic cells are not engulfed by phagocytes and can induce an inflammatory
response. Lack of recognition by phagocytic cells implies that the basic changes
in expressed proteins and signaling molecules that become expressed during
caspase activation are not present on necrotic cells[96]. The differences in
surface membrane expression has been exploited by researchers as a way to
differentiate cells that died via the apoptotic route from those that died by
necrosis; i.e., as with the use of TUNEL or annexin-V staining combined with flow
cytometry[97;98].
Role of Apoptosis in Inflammatory Cell Homeostasis:
Apoptosis in neutrophils (PMNs) is an important process in maintenance of
homeostasis. In the non-disease condition approximately 1-2 x 1011 PMNs are
produced in the bone marrow of human beings and released into circulation
daily[99]. Clearance by apoptosis is vital in order to avoid an overabundance of
these cells. During infection numerous factors can not only sequester PMNs to
the site of inflammation or infection, but also significantly decrease the rate of
constitutive apoptosis. The apoptotic process in PMNs is very similar to that
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observed in other cell types. It includes cytoplasmic condensation, aggregation
and cleavage of nuclear chromatin, and formation of apoptotic bodies[100].
Apoptotic events in PMNs also lead to recognition of these cells by phagocytes,
such as macrophages, which dispose of the neutrophil before loss of membrane
integrity leads to the accidental release of cytotoxic compounds[101]. Of equal
importance is loss of receptor mediated functional properties of apoptotic PMNs.
Apoptotic PMNs have been shown to exhibit decreases in cytokine production,
chemotaxis, phagocytosis, oxidative burst capabilities, and degranulation[102].
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III. Bacterial Endotoxin
Bacterial endotoxin is a lipopolysaccharide molecule (LPS) found in the cell wall
of Gram negative bacteria. LPS molecules are amphiphilic molecules consisting
of a hydrophilic polysaccharide portion covalently linked to a hydrophobic lipid
portion[103]. LPS is the predominant entity on the surface of bacterial cells; in
fact one bacterial body contains approximately 3.5x106 LPS molecules, covering
almost three-quarters of the bacterial surface[104]. When bacteria die and lyse,
large quantities of LPS are released into the extracellular environment.
Recognition of bacterial LPS by immune cells causes induction of the
inflammatory response, and a physiological cascade that can lead to endotoxic
shock and death[103].
Structure and Function of LPS Components:
As mentioned above bacterial LPS consists of a lipid portion covalently bound to
a polysaccharide portion. The polysaccharide portion can be sub-divided into
two regions; the O-specific chain and the core oligosaccharide. The O-specific
chain is a polymer of oligosaccharide units that can have as many as fifty
repeats[105]. The structure of the O-specific chain is highly variable, even from a
single bacterial strain, which allows LPS to exhibit a large amount of functional
variability. The core region of LPS is a hetero-oligosaccharide consisting of an
inner and outer portion. The outer portion of the core region is proximal to the Ospecific chain, while the inner portion is located adjacent to the lipid A portion of
LPS[104]. Of the two core protein components, the inner portion of the core
region is more highly conserved. This is reflected by the finding that regardless
of bacterial species, the inner core typically contains a 2-keto-3-deoxyoctonic
acid (Kdo) and L-manno-D-mannoheptose (L,DHep) portion. The outer portion of
the LPS core region exhibits more variability in structure, as illustrated by the
existence of at least 5 sub-types of outer core regions in E. coli[106]. Connected
to the inner core region is the lipid A portion of the LPS molecule. Lipid A is the
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most highly conserved component of LPS. Lipid A is an acetylated and
phosphorylated disaccharide of glucosamine[107]. Lipid A is well known as the
toxic and immunomodulating principle of bacterial LPS, as was demonstrated in
studies where chemically synthesized lipid A, devoid of polysaccharide
component, would induce biologic activities, both in vitro and in vivo that mimic
those observed by bacterial LPS[105].
Recognition of LPS by Host Cells:
The biological activities of LPS in regards to eliciting an immune response from
host cells is dependent on interaction between LPS, LPS binding protein (LBP),
and the cell surface receptor, CD14[108]. The first step in recognition of bacterial
LPS by immune cells is binding of LPS to LBP. LBP is a 60-kD serum
glycoprotein that contains a high affinity binding region for the lipid A region of
LPS[109]. Synthesized in hepatocytes, LBP is present in serum at <0.5µg/ml
under normal circumstances, but can rise to 50µg/ml within 24h of induction of an
acute phase response[110]. LBP opsonizes both LPS bound particles as well as
intact bacteria, and mediates attachment to phagocytic cells such as
macrophages by forming a complex with the cell surface receptor CD14[108].
There has also been evidence presented for a biphasic function of LBP. Some
recent studies have indicated that lower concentrations of LBP will intercalate
with the cell membrane of monocytes, enhancing the effects of LPS. While, at
higher concentrations, LBP will bind to LPS aggregates in the extracellular milieu
and inhibit their stimulatory properties[111]. Once LBP has bound to LPS it can
complex with CD14. CD14 is expressed as either a glycosylphosphatidylinostitol-linked membrane protein on macrophages, monocytes, and neutrophils
or as a soluble protein that can act as an LPS receptor for CD14 negative
cells[103]. It should be noted that LPS is capable of binding to CD14 without
LBP, but the presence of LBP greatly enhances this process[112]. Structurally,
CD14 lacks a transmembrane domain, which means that proper signal
transduction requires participation of another protein, toll-like-receptor-4 (TLR-4).
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This protein is a member of the toll-like receptor family and mediates the
activation of nuclear-factor-κB pathway[113].
Activation of immune cells leads to a number of cellular and physiological
responses. Macrophage activation by LPS induces production of
proinflammatory mediators such as tumor necrosis factor-α, interleukin-1, and
pro-inflammatory eicosanoids. LPS induces a chemotactic response in
neutrophils, as well as activates COX-2, and primes neutrophils for enhanced
production of LTB4[114;115]. Activation of the TLR receptor pathways have been
shown to induce or prime cytokine production, superoxide production, and Lselectin shedding in human neutrophils[116]. Neutrophil exposure to LPS also
induces a survival pathway through inhibition of constitutive neutrophil
apoptosis[116]. Activation of the inflammatory response by LPS is linked with
induction of numerous inflammatory diseases, such as endotoxemia or sepsis,
the latter of which will be discussed in further detail [117;118].
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IV. Systemic inflammatory Response Syndrome
Introduction to SIRS:
The clinical definition of sepsis is the systemic inflammatory response to
documented infection[119]. It has since been recognized that other factors
aside from bacterial infection can trigger an inflammatory response. The term
Systemic Inflammatory Response Syndrome (SIRS) was put forth by the
American College of Chest Physicians and the Society of Critical Care Medicine
at a consensus conference in 1992 to define the inflammatory response
classically referred to as sepsis, independent of cause[120]. Clinically SIRS is
diagnosed by the presence of more than one of the following symptoms: body
temperature greater than 38ºC or less than 36º C, heart rate greater than 90
beats per minute, a respiratory rate greater than 20 breaths per minute, or
hyperventilation indicated by PaCO2 of less than 32mmHg. Hematologically,
there is an alteration of white blood cell count; either greater than 12,000 cu/mm
or less than 4,000 cu/mm, and possibly accompanied by an increase (10%) of
immature neutrophils[120]. Further criteria describe the severity of the
inflammatory reaction based on the presence of additional symptoms associated
with the progression of sepsis. Severe sepsis is defined as organ dysfunction or
sepsis-induced hypotension. The most severe form of sepsis, septic shock,
meets the previous criteria along with sepsis-induced hypotension that persists
regardless of fluid resuscitation and accompanied by sepsis induced organ
dysfunction. Epidemiologic studies of sepsis indicate variable hospital and
intensive care unit occurrence rates of 2-11% of all adult admissions, with a
mortality rate of about 49%[121].
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Etiology of Sepsis:
The initial onset of sepsis occurs with a bacterial infection. During their life cycle,
bacteria shed numerous antigens, such as LPS, which are detectable by host
immune cells. Sufficient numbers of bacteria may be able to release enough of
these antigens to spill over into the host circulatory system. Once in the
bloodstream antigens are recognized by host immune cells. Of particular
importance for this step are macrophages[122]. Macrophages are specialized
phagocytic white blood cells that are present in areas such as the sub-epithelium
of the skin, alveolar tissue of the lung, or lining the blood sinusoids of the liver,
spleen, and lymph nodes[119]. Macrophage activation leads to release of
soluble factors, cytokines, that recruit and activate other cells; thus beginning the
inflammatory cascade[122]. The proinflammatory cytokines also trigger release
of several anti-inflammatory mediators that inhibit immune cell function and
attempt to localize the inflammatory response[123]. This anti-inflammatory
cascade provides a balance to the immune response to infection or injury.
Inflammatory Mediators in SIRS/Sepsis:
Macrophage activation by bacterial LPS initiates release of chemical mediators
which are responsible for the pathology of sepsis. This process begins with
formation of a complex between LPS with LPS binding protein (LBP). This
complex is recognized and activates the CD14 complex found on the cell
membrane. TLR4 then transduces this signal through a signaling pathway that
mediates degradation of the inhibitor molecule for nuclear factor (NF)κB.
Activated NFκB is translocated to the nucleus of the cell, where it binds with DNA
and promotes transcription of numerous genes responsible for production of a
host of pro-inflammatory cytokines including; tumor necrosis factor-α (TNFα),
interleukin (IL) 1, granulocyte-colony stimulating factor (G-CSF), interferonγ (IFN-γ), IL-2, IL-6, and IL-12[122].
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Tumor Necrosis Factor α: TNFα is a 17-kDa, 157 amino acid polypeptide that is
produced mainly by monocytes and macrophages. TNFα exists in both a
membrane bound and soluble form. Soluble TNFα is formed by cleavage of
extracellular domain of the membrane bound molecule by metalloproteinase
compounds, and is a 17-kDa molecule as compared with the membrane bound
TNFα molecule which is 26-kDa[124]. Cleavage of soluble TNFα increases
during infection or inflammation. Leading to an increase of circulating TNFα,
which has been shown to peak approximately one hour following insult[125].
TNFα initiates its effect by binding with two distinct surface receptors; a 55kDa
receptor (TNFRI) and a 75kDa receptor (TNFRII). Originally it was believed that
TNFRI was the primary receptor by which signal recognition of TNFα was
received because of its higher affinity for the soluble form of TNFα. However, it
was later found that TNFRII plays an important role in sensing the presence of
membrane bound TNFα in autocrine and paracrine interactions[126;127].
Although TNFα binding to either of these receptors triggers activation of NFκB,
other factors along the signal transduction pathways allow the molecule to exhibit
different results. For example, activation of TNFRI and the proceeding signal
transduction pathway initiates apoptosis, while activation of the TNFRII and the
ensuing signaling cascade induces an increase in cytokine production.
Transcription and expression of these receptors is under genetic control, which
allows different levels of expression. These expression levels modulate the
likelihood of interaction with ligands[128]. TNFα has a variety of activities in
numerous tissue types. For example, NFκB activation in vascular endothelial
cells by TNFα up regulates expression of adhesion molecules such as E-selectin,
ICAM-1, and VCAM[119]. Increased expression of these molecules alters the
surface of vascular endothelium and causes immune cells such as PMNs,
macrophages, and CD4+ T cells to adhere and roll along the endothelium. These
molecules also alter the structure of vascular endothelium allowing diapedesis of
inflammatory cells from circulation to sites of infection, as well as increasing

46
vascular permeability[122], all of which are important factors with sepsis
associated disorders such as acute respiratory distress syndrome (ARDS).
TNFα injection induces the production and release of other proinflammatory
cytokines such as IL-1β, IL-6, IL-8, and IL-12, as well as inducing SIRS-like
symptoms including: fever, hemodynamic abnormalities leukopenia, coagulation
disorders, and increased production of liver enzymes[129].
Interleukin-1: IL-1 is another cytokine produced by monocytes in the acute
phase of SIRS. IL-1 has two subtypes; IL-1α, and IL-1β. IL-1α is mainly found
in the cellular compartment, while IL-1β is the predominant form found in
circulation during sepsis[130]. There have been two receptors (IL receptor type I
and IL receptor type II) identified for IL-1α and IL-1β. The structural similarity of
the molecules allows them both to activate each receptor type, although IL-1
receptor type II is thought to be biologically inactive[119;119;130] which means
that it may serve to negatively regulate IL-1 function. IL-1 is not normally found
in human plasma, and when endogenously or exogenously administered induces
many of the same symptoms as TNFα[129]. The overlapping role of these
cytokines is thought to create either a synergistic, or additive effect that amplifies
the severity of the inflammatory response[123]. One effect of IL-1 is rapid
activation of cytosolic phospholipase A2, which is an important molecule in
conversion of tissue polyunsaturated fatty acids such as arachidonic acid (AA) to
lipid-based inflammatory mediators[131]. This activation has been linked with an
increased production of prostaglandin E2 (PGE2), which is recognized by the
central nervous system triggering induction of fever[132]. Pretreatment with
cyclooxygenase inhibitors decreases some of the symptoms, such as fever and
headache, that are induced when IL-1 and TNFα are coadministered[133]. IL-1
also induces production of other cytokines such as IL-1, IL-6, IL-8, as well as
TNFα. Blocking activity of IL-1 using receptor antagonists can prevent the
increase of other interleukins, but not TNFα[134]. IL-1 also up-regulates
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production and expression of TNFRII which increases the effect of TNFα on
cells[135].
Interleukin-6: IL-6 is a 21-kDA protein produced in many cell types, including
monocytes. IL-6 activates B and T lymphocytes[119]. IL-6 release from resident
liver macrophages (Kupffer cells) signals the liver to produce acute phase
proteins. This results in increased circulating coagulatory, transportation, and
tissue remodeling factors, as well as decreased proteins from the cytochrome
p450 complex. IL-6 also lowers circulating levels of cholesterol and fatty acids.
IL-6 alters the carrier molecules of fatty acids by increasing their affinity with
activated macrophages, thereby providing more energy to the immune
response[122]. IL-6 has been shown to induce fever by stimulating PGE2
production in the central nervous system[136]. IL-6 has also been shown to
increase cytotoxicity of PMNs by augmenting release of elastase[137]. Although
the role of IL-6 in sepsis is not as clearly defined as IL-1 or TNFα, an increase in
IL-6 has a significant correlation with mortality in septic patients and severity of
inflammation-associated organ dysfunction[119].
Interleukin-8: IL-8 is a small protein that is a member of the chemokine family of
cytokines, is produced by a variety of cells, and is up-regulated by various factors
such as LPS, TNFα, and IL-1[138]. The primary function of IL-8 is to activate
and chemoattract PMNs to sites of inflammation[129]. IL-8 operates through
CXCR1 and CXCR2 receptors, which are in the seven transmembrane Gcoupled protein receptor groups. IL-8 interaction with PMNs causes shape
change and increases cell surface expression of integrin molecules, increasing
PMN adherence to vascular endothelium, as well as increasing production of
reactive oxygen metabolites in PMNs[119].
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Interleukin-12: Proinflammatory IL-12 is a heterodimer consisting of a p35 and a
p40 subunit, both of which are encoded by separate genes. IL-12 production
occurs predominantly in macrophages and monocytes and targets T cells and
natural killer cells. Activation of these cells by IL-12 induces production and
release of interferonγ (IFN-γ), which acts on monocytes to increase production of
proinflammatory cytokines including IL-12[119;130]. The role of IL-12
heterodimer may enhance the inflammatory response by creating a positive
feedback loop for cytokine production between T cells, natural killer cells, and
macrophages.
Anti-inflammatory Cytokine Cascade in SIRS/Sepsis:
In order to prevent host mortality from an uncontrolled inflammatory response, an
intricate system has evolved to attenuate the effects of the inflammatory
cascade. This system involves cytokines and signaling pathways that reduce
production of proinflammatory mediators, soluble receptors that can bind
inflammatory stimuli before it can interact with target cells, as well as cellular
adaptations that reduce ability of cells to respond to stimuli.
IL-10 is a homodimeric 160 amino acid protein produced by a variety of cells. IL10 inhibits production of TNFα, IL-1, and IL-8[129]. In PMNs, IL-10 reduces
production of these proinflammatory cytokines in LPS-stimulated cells, enhances
production of IL-1 receptor antagonists (IL-1ra), and reduces PMN migration
during LPS induced lung injury[139].
Interleukin-4: IL-4 is a 20-kDa glycoprotein produced by activated Th2 cells,
basophils, and mast cells. IL-4 targets monocytes and PMNs and inhibits
secretion of proinflammatory cytokines[119].
Interleukin-10: Of the anti-inflammatory cytokines, IL-10 is perhaps the most well
studied in models of bacterial infection. IL-10 is an 18-kDa polypeptide that is
synthesized by T cells, B cells, and monocytes. IL-10 synthesis is stimulated by
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TNFα, IL-1, IL-6, and IL-12, as well as bacteria and bacterial products such as
LPS[130]. IL-10 production occurs maximally after about 24 hours in patients
with severe sepsis, and has been shown to prevent LPS-associated mortality in
laboratory animals[119].
Other anti-inflammatory cytokines: Certain cytokines seem to serve dual roles in
inflammatory regulation. IL-6 for example, stimulates differentiation and
proliferation of T cells, B cells, and induces acute phase protein synthesis. It
inhibits IL-1 and TNFα production in monocytes[140], and induces production of
IL-1 receptor antagonist and soluble TNFα receptors, which blocks effects of
their proinflammatory ligands[141]. The p40 subunit of IL-12 has the ability to
dimerize with the p35 subunit, or to form a homodimer with another p40 subunit.
This homodimer of p40 subunits can bind to the IL-12 receptor with similar affinity
as the p40/p35 complex without inducing a cellular response[130].
Soluble Inhibitors of Proinflammatory Cytokines: Anti-inflammatory cytokines
function by inhibiting production of their proinflammatory cousins. However,
there are also mechanisms to inhibit action of potentially toxic proinflammatory
cytokines after they have been released from the cell.
Soluble TNFα: As previously mentioned, TNFα plays a major role in induction
and maintenance of the inflammatory response. TNFα works synergistically with
IL-1 to activate other pro-inflammatory cytokines and to direct the host response
to infection and injury; however, excessive tissue production of TNFα can cause
detrimental effects. Therefore, aside from a decrease in production caused by
presence of anti-inflammatory cytokines, other mechanisms exist that blunt the
effect of TNFα that is already present. These natural inhibitors are the soluble
TNFα receptors (sTNFR). They are produced by numerous cell types as they
shed the extracellular domains of their membrane bound TNFα receptors[142].
This shedding can be induced by a number of stimuli, including IL-10, IL-1, and
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TNFα itself[130]. There are two varieties of sTNFR, a 30-kDA and a 40-kDA
species, which share sequence homology with extracellular domains of TNFRI
and TNFRII, respectively[142]. The presence of sTNFRs serves a twofold
purpose. First, shedding the extracellular portion of their TNFR effectively
desensitizes cells to TNFα. Second, sTNFRs can still bind to the extracellular
TNFα, preventing it from acting as a ligand for membrane bound TNFRs.
Soluble and membrane bound IL-1 inhibitors and receptor antagonists:
Like the mechanisms that exist for TNFα, there are several methods for limiting
biological activity of circulating IL-1. First, is the existence of a non-functional
receptor, IL-1 receptor, type II, which binds to IL-1β with high affinity[130]. IL-1
receptor type II exists in two forms, either as a membrane bound molecule, or as
a soluble form. Like sTNFR soluble IL-1 receptor type II is made up of the
cleaved portion of the extracellular domain of its membrane bound
counterpart[143]. This cleavage can be induced by a variety of stimuli including
LPS and TNFα[144]. IL-1 receptor type II is a unique cytokine receptor because
it does not provide signal transduction once bound to IL-1β. This along with the
high affinity to IL-1β allows both the soluble and membrane bound forms of IL-1
receptor type II to act as a decoy to IL-1β[143].
Another mechanism for decreasing the biological impact of IL-1 is IL-1
receptor antagonist (IL-1ra). IL-1ra is a 22-kDa protein that shares sequence
homology with IL-1β. IL-1ra binds preferentially to the active IL-1 receptor (IL-1
receptor type I). However, crucial sequence differences in IL-1ra prevent proper
formation of the complex required to incite signal transduction once IL-1ra is
bound[143].
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V. Complications Secondary to Sepsis
Multiple Organ Dysfunction Syndrome:
As the severity of sepsis progresses it is not uncommon for organ dysfunction to
occur. In fact, the cause of death in most sepsis patients is not from infection,
but from organ failure. The occurrence of multiple organ failure during sepsis is
so prevalent that the condition has been termed multiple organ dysfunction
syndrome (MODS). Organ dysfunction occurs when the functional status of that
organ has been altered to the point that it is no longer able to maintain
homeostasis. This change is attributable either primarily or secondarily to insult,
and this route determines whether MODS is defined as primary or secondary
MODS. In most cases of sepsis, MODS would be defined as secondary, as it is
typically a result of host response to insult[120].
Lung Injury in MODS:
Lung dysfunction occurs in about 60% of septic patients with MODS[145]. The
high incidence of lung involvement is due to several factors related to the organ
and its function. Because of the large interface of the lung with the external
environment, it has developed an intricate and highly sensitive defense
mechanism to protect against microbial invasion. In this system two cell types
have been identified as being vital for host defense; the alveolar macrophage
and the PMN. Resident alveolar macrophages have perhaps the most important
role of any monocyte cell type in host defense of microbial invasion. These cells
are positioned within the surfactant layer of the alveolus. They are directly
responsible for detection and clearance of bacteria in the alveolar space[146].
Aside from the direct antimicrobial role of the alveolar macrophage, this cell can
recruit circulating PMNs to the alveolar lumen through a series of chemical
mediators. These mediators include protein derived cytokines as well as lipid
derived eicosanoids. Several recent studies have suggested that in models of
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lung injury eicosanoid products play the predominant role in cell signaling. This
is based on findings that alveolar macrophages are capable of enhanced
eicosanoid release as compared with monocytes or macrophages from other
tissues[147]. Alveolar macrophages are primed for an increased production of 5LO eicosanoid products, specifically LTB4[41]. It is thought that this difference
exists as a mechanism to expedite sequestration of PMNs to the site of bacterial
invasion, as the enzymes responsible for eicosanoid synthesis are constitutively
present and do not require de novo synthesis, as is the case for cytokine
production enzymes. Release of eicosanoid mediators swiftly induces the
chemotaxis of circulating PMNs from the lung microvasculature to the alveolar
lumen. Once recruited, PMNs become activated by cytokines and eicosanoids.
This activation leads to release of bactericidal and cytotoxic compounds,
resulting in PMN-mediated tissue damage, setting the stage for lung injury.
During sepsis the sensitivity and enhanced response of immune cells in the lung
places this organ at higher risk of being involved in development of secondary
MODS. Like sepsis, lung dysfunction follows along a spectrum of severity. The
progression of tissue damage may lead to conditions known as acute lung injury
(ALI), and in the most severe cases, acute respiratory distress syndrome
(ARDS).
Acute Lung Injury and Acute Respiratory Distress Syndrome:
ALI is defined as a syndrome of inflammation and increased permeability that is
associated with a constellation of clinical, radiologic, and physiologic
abnormalities that cannot be explained by, but may coexist with, left atrial or
pulmonary capillary hypertension[148]. Clinical diagnosis of ALI is determined by
acute onset, PaO2/FiO2 levels of less than 300mm Hg regardless of positive-end
expiratory pressure (PEEP), bilateral infiltrates observed on frontal chest
radiographs, and a pulmonary artery wedge pressure of greater than 18mm Hg.
As with SIRS, ALI is considered to be a disease that covers a broad spectrum of
severity. The most severe form of ALI is acute respiratory distress syndrome
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(ARDS). ARDS follows the same definition as ALI with the exception that the
PaO2/FiO2 level must be less than 200mm Hg[148].
Pathology of ARDS:
ALI/ARDS progresses through three overlapping phases; exudative, proliferative,
and fibrotic phases. The exudative phase of ALI/ARDS is denoted by influx of
protein-rich edema fluid into alveolar spaces, as well as increased local
production of proinflammatory cytokines and eicosanoids such as LTB4, TNFα,
IL-1, and IL-8 by pulmonary macrophages[149]. Release of these inflammatory
signals is important for the development of ARDS. Lungs extracted from patients
that died during this phase are heavy and rigid, often weighing over 2000g. The
lungs also become discolored, turning from their normal color to a reddish-blue or
grey hue[150;151]. Alterations in endothelial cell function begin to allow
proteinaceous fluid to seep from the vasculature to the interstitial space. Fluid
accumulation widens the interstitial space between the pulmonary epithelium and
vascular endothelium. This space is normally 2.2µm, which includes the
basement membrane as well as specialized type 1 alveolar epithelial cells. Type
1 alveolar epithelial cells are flattened in appearance and typically compose 8%
of lung epithelial parenchyma, while covering a surface area of approximately
5098µm. Type 1 alveolar epithelial cells operate in conjunction with type 2
alveolar epithelial cells, which are larger cuboidal cells that typically comprise
about 16% of the alveolar parenchyma while only covering a surface area of
about 183µm[151]. Type 2 alveolar epithelial cells produce surfactant, which is
responsible for reduction of surface tension at the alveolus[150;152;153]. Both
alveolar epithelial cell types are connected by tight cell junctions that form a
relatively impermeable barrier. Sodium and potassium pumps found on type 2
alveolar epithelial cells actively transport ions from alveoli to pulmonary capillary
beds. These pumps operate in tandem with aquaporins found on type 1 alveolar
epithelial cells facilitating fluid clearance during normal functioning[150;151;154].
The interstitial distance and normal functioning of alveolar epithelial cells is
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crucial for proper gas diffusion and fluid exchange. As fluid accumulation in the
interstitial space continues, the alveolar ducts themselves begin to dilate,
decreasing the air spaces to less than 1mm. Eventually, edema fluid infiltrates
the alveolar lumen. Histologically, this first appears as a hyaline membrane
along the alveolar ducts. This membrane consists of condensed plasma proteins
and cell debris that have leaked into the alveolus. This hyaline membrane is
often associated with a selective early loss of adjacent epithelial cells[151]. As
ALI/ARDS develops, activated PMNs appear in the pulmonary vasculature,
interstitial spaces, and eventually in the alveolar lumen[149;150;155]. PMN
activation leads to release of nitric oxide (NO) and reactive oxygen species,
proteases, elastase, and collagenase. These cytotoxic compounds are
responsible for the damage caused to type 1 and type 2 alveolar epithelial cells.
Type 1 alveolar epithelial cells are very susceptible to PMN-mediated damage,
and significant loss leads to areas of exposed basement membrane and
disruption of normal fluid exchange contributing to alveolar flooding[150-152].
Following the exudative phase of lung injury is a period of tissue
restructuring and overall lung remodeling known as the proliferative phase[150].
The overall appearance of the lung during this phase is described as being a
glistening pale grey color, having a very solid and slippery feel to it, and having
very small air spaces that may even be absent in some areas[151]. A key
feature of this phase is increased accumulation of interstitial myofibroblasts.
Increased production of transforming growth factor β (TGFβ), and autocrine IL1β-dependant IL-6 up-regulation activates fibroblasts which, deposit collagenous
connective tissue along the wall of the alveoli[156;157]. The increased amount
of fibrous tissue in the alveolar septa leads to decreased airspace in the alveolar
ducts and in the space of individual alveoli, further decreasing efficiency of gas
exchange. Lesions in alveolar epithelium from loss of type 1 alveolar epithelial
cells allow fibroblast infiltration into the alveolar lumen. Here the fibroblasts
begin to convert the proteinaceous edema fluid into connective tissue through
collagen deposition. This effectively converts areas that were previously air
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spaces in the alveolar lumen to interstitial tissue. Type 2 alveolar epithelial cells
rapidly proliferate, and begin to differentiate into type 1 alveolar epithelial cells in
an attempt to cover old basement membrane and newly deposited fibrotic
connective tissue as well[150-152]. Another mechanism of lung remodeling is
alveolar collapse. This is observed after injury to the alveolocapillary unit, when
the actual alveolar walls collapse either partially or completely. Fibroblast
infiltration and conversion of edema fluid to fibrotic tissue followed by epithelial
cell growth effectively seals these areas from the rest of the lung. This tissue
remodeling leads to a lung that contains significantly fewer, but larger alveoli with
dilated alveolar ducts as compared to the uninjured lung.
The final stage, or the fibrotic stage, occurs 3-4 weeks following the onset
of ARDS. The lungs of surviving patients become heavily scarred, noncompliant, end-stage organs, and is described as having a coarse, cobblestone
surface due to heavy scarring and restructuring[150;151]. The parenchymal
surface is pale and spongy, consisting of a honeycomb network of scar tissue
and microcystic air spaces. Microscopically alveolar walls are sparsely cellular
and thickened by collagenous connective tissue[151].
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VI. The Neutrophil
The polymorphonuclear neutrophil (PMN) is considered to be the primary effector
cell in innate immunity. This cell type has evolved a variety of biological agents
to aid in tissue transit and bacterial killing. The PMN contains more than 30
histotoxic agents, and has been implicated in the pathogenesis of numerous
inflammatory disease states[158].
Role of PMNs in ARDS:
The tissue damage and pathophysiology of ARDS is driven by an aggressive
inflammatory response. The initiation of this response is choreographed by the
alveolar macrophage, which acts through various inflammatory mediators to
rapidly recruit PMNs to lung tissue. Recruited PMNs actively migrate to the site
of infection or inflammation. Bactericidal action of PMNs occurs by phagocytosis
of the invading organism, or by release of cytotoxic granules and reactive oxygen
species into the extracellular environment[159]. During normal immune function
specialized complexes within the PMN allow the cell to produce highly reactive
oxygen species such as superoxide radicals, hydrogen peroxide, and hydroxyl
radicals. These compounds along with numerous proteases found in specialized
granules and secretory vesicles are used to kill ingested microbes[160;161].
PMNs can also release these granules and reactive oxygen species into the
extracellular environment. These compounds interact with microbes in a variety
of manners, eliciting damage to their cell membranes, disabling key metabolic
pathways, and causing damage to their DNA[159;162]. The critical role of the
neutrophil in ARDS was first suggested in studies in which LPS injections were
shown to increase PMN sequestration to pulmonary tissue[163], and that PMN
depletion prior to insult could prevent ARDS symptoms[164]. Under normal
circumstances PMNs constitute approximately 0.08% of the cell population found
in the lung. However, bronchoalveolar lavage fluid cell counts from patients with
ARDS have demonstrated that the PMN population increases to constitute as
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much as 70% of the cell population[165]. The release of potent neutrophil
attractants and activating factors such as LTB4, IL-8, TNFα, IL-1, and IL-6 by
resident alveolar macrophages stimulate the pulmonary microvascular
sequestration and activation of PMNs. There is some debate as to the control
that the PMN has on the release of cytotoxic compounds upon activation. There
have been some reports in the literature that would indicate PMNs typically exert
a fair amount of control in their response to stimulation[162], while others report
that damage caused by PMNs is due to their lack of control mechanisms[145].
This makes the increased presence of PMNs in pulmonary tissue a key factor in
the tissue damage and lung injury during SIRS/sepsis and ARDS
[145;150;152;165]. Resolution of ARDS is highly dependent on clearance of
PMNs from the lung, while preventing the release of cytotoxic contents of the
cell. Programmed cell death, or apoptosis plays a critical role in accomplishing
this task. Apoptotic PMNs lose their ability to produce and release cytotoxic
compounds, and alveolar macrophages recognize specific signaling molecules
that are present on the extracellular membranes of these dying cells.
Macrophages phagocytize the apoptotic PMNs, preventing granule and
superoxide release[166].
Granules and PMN Function:
The specialized nature of PMNs as highly adaptable cells of immune function
stems from their granules and secretory vesicles. For decades it was believed
that these structures, unique to PMNs, were simple storage compartments for
bactericidal compounds. Indeed, PMN granules contain a vast arsenal of
proteolytic and oxidative chemicals that, when released into the extracellular
environment or fused with the phagocytic vesicle, efficiently kill bacteria[162].
However, the membrane portion of PMN granules and secretory vesicles contain
numerous protein receptors and ligands that become expressed upon fusion of
the granule with the cell membrane[161]. The expression of these factors allows
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the PMN to effectively interact with the extracellular environment, transforming it
from a passively circulating cell to an agent of the innate immune system.
Neutrophil Activation:
Neutrophils are highly specialized cells of immune function. Features of these
cells allow them to rapidly shift from a passive role as a component of the blood
milieu, to aggressive and effective cytotoxic cells in presence of infected or
inflamed tissue. This process is mediated by several signaling cascades,
including cytokine, chemokine, and eicosanoid release. These factors initiate
cellular changes that recruit, prime, and induce the cytotoxic activity of
neutrophils.
Neutrophil sequestration and activation occurs in a series of steps that
alter form and function to allow them to first migrate to the site of infection or
inflammatory stimulus and then to release their cytotoxic components to effect
bacterial killing. There are a variety of stimulating factors that can interact with
PMNs to effect these changes. These can include bacterial products such as
LPS, or cytokine or eicosanoid products released by macrophages. Regardless
of source, activation of PMNs induces cytokine production as well as
physiological changes in the cells such as the up-regulation of adhesion
molecules, alteration of PMN shape, and killing potential[167]. One of the effects
of PMN activation by LPS is a change in the cytoskeletal structure of the cells
that prevents them from being able to alter their shape to squeeze through small
capillary beds. It has been suggested that cytoskeletal alterations may play a
role in the influx of some of the PMNS in the primary phase of ARDS. These
PMNs become trapped in the pulmonary vasculature and begin releasing
cytokines. This cytokine release recruits more PMNs to the area, where they
become activated and begin emigrating to the pulmonary parenchyma[167].
Although LPS can directly exert an effect on PMN function, alveolar
macrophages play a more prominent role as effectors of PMN function during
sepsis and ARDS. For example, IL-1 and TNF-α have both been shown to be
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potent activators of PMNs. These two cytokines operate through different
surface receptor families that converge with induction of NFκB translocation to
the nucleus leading to PMN activation[145;145;168]. PMN exposure to TNF-α
leads to production and release of elastase, superoxide ion, hydrogen peroxide,
soluble phospholipase A2 (sPLA2), platelet aggregating factor (PAF),
thromboxane A2, and leukotriene production[145]. IL-1 has several overlapping
effects on PMNs, stimulating production and release of elastase, collagenase,
and prostaglandins. Another factor in PMN infiltration of lung tissue is IL-8. As
previously mentioned IL-8 is a member of the chemokine family that is produced
primarily in the lung by pulmonary macrophages and is a potent chemoattractant
of PMNs. IL-8 concentrations were higher in BAL fluid from hospitalized patients
that subsequently developed ARDS as compared with those who did not fully
develop the condition[169].
Neutrophil Migration:
The crucial role of PMNs as the primary defensive cell against microbial infection
comes from the attribute of directed action and controlled release of cytotoxic
granules at the site of inflammation. The PMN inflammatory response is
considered to be a multi-step process. The first phase of PMN activation is the
recruitment phase. During this phase PMNs undergo an alteration of receptors
and adhesion molecules expressed on the surface of the cells. These alterations
in the PMN membrane change the cells from passive circulating cells to active
and potent participants in innate immunity. PMN recruitment occurs in three
distinct phases; rolling, firm adhesion, and finally extra-vascular migration[169].
PMN recruitment involves a series of regulated exocytotic events involving
intracellular granules and secretory vesicles that gradually change the functional
state of PMNs[162].
The rolling phase of PMN migration involves co-stimulation of vascular
endothelium near the site of inflammation. Activated vascular endothelial cells
translocate P-selectin to their luminal membranes. This endothelial cell ligand
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activates P-selectin glycoprotein ligand-1 (PSGL-1) on the PMN. The interaction
between these ligands promotes PMN rolling along the endothelium[170].
Activated endothelial cells also up-regulate E-selectin and the glycosylated cell
adhesion molecules (glycams) that are ligands for PMN adhesion molecules
CD15 and L-selectin, respectively[145;162;167].
After the velocity of the circulating PMN has been slowed by interactions
between selectins, a second series of adhesion molecules are expressed that
form a firm adhesion between PMNs and activated vascular endothelial cells.
This adhesion is mediated primarily by increased expression of the β2 integrin
CD11/CD18 on the surface of the PMN. CD11/CD18 is found in high
concentrations along the membranes of secretory vesicles. The mobilization of
these vesicles during this phase enriches the surface of the PMN with
CD11/CD18, while inducing shedding of L-selectin. These changes allow
interaction between the β2 integrins and intercellular adhesion molecules
(ICAMs) found on the vascular endothelial cells, forming a firm adhesion between
the PMN and vascular endothelium. Interactions between CD11/CD18 and the
ICAMs also prepare PMNs and local endothelial cells for
extravasation[145;167;171].
The final step in PMN migration is extravascular migration to the site of
inflammation. Migration is directed by a number of factors, primarily the
existence of a concentration gradient of chemoattractants that draw the PMN to
the tissue. This process is localized at endothelial cell junctions and involves
platelet-endothelial cell adhesion molecule-1 (PECAM-1). PECAM-1 is found in
high concentrations in junctions between vascular endothelial cells. It has been
shown to act as a direct adhesion molecule for PMNs, and may also provide a
measure of protection to preserve the permeability of vascular endothelium.
Blocking PECAM-1 by monoclonal antibodies decreases PMN extravascular
migration significantly[171;172]. Following migration through the junctions of
vascular endothelial cells, PMNs release gelatinases, and collagenolytic
metalloproteses that degrade the basement membrane surrounding blood
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vessels. As PMNs proceed toward the site of inflammation special matrixsensing receptors are expressed on the cell membrane. These receptors
choreograph release of collagenases and serine proteases that allow the PMN to
effectively “drill” through the tissue toward chemotactic stimuli[145;162;165].
Cytotoxic Activity of PMNs:
PMN mediated bacterial killing can occur by one of two mechanisms. Primarily,
PMNs act by engulfing microbes in a phagocytic vacuole. Once internalized
granules mobilize and merge with the membrane of the vacuole. This allows
release of granular contents into a controlled microenvironment. Secondarily,
mobilized granules and secretory vesicles interact with PMN cell membranes to
exocytose their contents into the extracellular environment. This second type of
granule release is not only involved with bacterial killing, but is also an important
mechanism by which the PMN migrates to sites of infection across extracellular
tissue[162;167].
Upon reaching the site of infection PMNs have several tools at their
disposal to kill invading microbes. First, is an arsenal of proteolytic enzymes,
which are stored in the granules of the PMN. Granular storage protects the PMN
from its own arsenal of cytotoxic compounds while providing a mechanism for a
controlled response upon stimulation[158]. Fusion of these granules with either
the cell membrane or the phagocytic vacuole causes release into the
microenvironment. As previously mentioned there are several granule types,
each having different protein constituents for bacterial killing. Primarily
azurophilic granules contain high concentrations of myeloperoxidase, but also
contain α-defensins, and bacterial permeability increasing protein[173]. These
granules also have high concentrations of proteases such as proteinase 3,
cathespin G, and elastase[161]. The α-defensins are small cationic antimicrobial
and cytotoxic peptides that perforate the cell membrane leaving small multimeric
holes[174]. Myeloperoxidase plays a vital role in the formation of reactive
oxygen metabolites from NADPH oxidase-derived hydrogen peroxide[159].
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Bacterial permeability increasing protein binds with membrane LPS on gram
negative bacteria and causes a rearrangement of the lipids in the outer and inner
membranes of the bacteria[175]. Proteases are examples of PMN components
directed against tissue of the intercellular matrix. These compounds quickly
degrade components such as type IV collagen, vitronectin, fibronectin, and
elastin.
Specific and gelatinase granules contain high levels of bactericidal and
matrix degrading proteins. These include lysozyme, lactoferrin, and matrix
metalloproteases[176-178]. Lysoszyme is a protease that is present in all
granules; it is found in highest concentrations in the specific granules. Lysozyme
cleaves the peptidoglycan polymers of bacterial cell walls. Lysozyme also acts
as an anti-inflammatory agent by binding to LPS, and reducing its ability to bind
with CD14 receptors. Lactoferrin is found in specific granules, and impairs
bacterial growth through a sequestration of Fe2+. Matrix metalloproteases are
found primarily in gelatinase granules. These compounds include leukolysin and
gelatinase, both of which are responsible for the degradation of the extracellular
matrix. These proteases are particularly effective against collagens, fibronectin,
proteoglycans, lamnin, and gelatin. Gelatinase granules are mobilized in
response to activation of specialized matrix sensing receptors, allowing the PMN
to tunnel to the site of infection[179]. Gelatinase, in particular, has been
implicated for its role in the disruption of the alveolar basement membrane, and
edema formation in ARDS[180].
The second mechanism by which PMNs deal with infection is by
production of reactive oxygen species (ROS). ROS production is managed by
the NADPH oxidase enzyme complex[160]. In its native state the NADPH
oxidase enzyme is stored in four separate parts. The primary component,
cytochrome b558 is found in abundance on the surface of specific granules.
Cytochrome b558 becomes expressed on the phagocytic vacuole and the cell
membrane following fusion with specific granules. Cell activation also induces
relocation of other constituents of the NADPH oxidase complex, p47phox, p67phox,
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and p40phox, along with GTP binding protein to b558, thereby completing the
complex[181]. Once assembled, the NADPH oxidase complex facilitates transfer
of electrons from cytosolic NADPH to molecular oxygen in either the phagocytic
vacuole or the extracellular environment. This transfer is dependent on
phosphorylation of p47phox at several serine residues. This phosphorylation
changes the structure of the molecule to allow a low affinity binding of NADPH.
Activation of the NADPH complex results in formation of superoxide (O2-)
radicals, which are bactericidal in their own right, but interact with the
myeloperoxidase enzyme complex to form hydrogen peroxide (H2O2). This
reaction accounts for the majority of the oxygen consumption observed during
the respiratory burst of the PMN[159;182]. Myeloperoxidase can then use H2O2
to oxidize a number of other molecules to form other reactive species. One of
the more unique ROS formed by myeloperoxidase activity is hypochlorous acid
(HOCl). HOCl is a strong non-radical oxidant of a wide range of biological
compounds, and accounts for much of the bactericidal activity of ROS
generation[183]. Further, HOCl along with superoxide radicals are used by
myeloperoxidase to form an even more reactive compound, the hydroxyl radical.
There is some debate as to the actual in vivo formation of these molecules by
PMNs; however, they have been shown to be highly reactive with most biological
compounds causing DNA modification and strand breaks, enzyme inactivation,
and lipid peroxidation[159]. Myeloperxidase can also combine catalytically HOCl
with amine groups to form chloramines. Chloramines are long lived oxidants
that react with thiols and thioesters. The degradation of chloramines leads to the
formation of toxic aldehyde compounds[159;160].
As illustrated here, PMNs posses a number of systems designed to
destroy invading microorganisms. During inflammatory conditions such as
ARDS, in which there is an overabundance of PMNs these same compounds can
cause massive damage to host tissue as well. There are a number of theories as
to why this occurs, one of which is the “Proteinase-antiproteinase balance theory”
of PMN inflammation[158]. In order to avoid PMN-mediated tissue damage
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during infection, host cells have developed several counteracting compounds
that inactivate PMN-derived proteases and ROSs. During acute PMN influx
release of cytotoxic compounds effectively overwhelms the counterbalancing
compounds and cause damage to host tissue. Release of ROS and proteases
by PMNs can either be intentionally via granule exocytosis or by loss of PMN
membrane integrity during necrosis. Apoptotic PMNs retain membrane integrity
as assessed by vital dye exclusion assays. Further, initiation of apoptosis in
PMNs leads to a decrease in granule mobilization in response to stimulus. In
these regards, apoptosis plays a major role in PMN clearance without release of
cytotoxic granules[102;184].
Neutrophil Apoptosis and ARDS:
The clearance of PMNs from the lung during ARDS or ALI without the release of
cellular content is a vital step in the resolution of inflammation. Recognition of
apoptotic PMNs by alveolar macrophages triggers phagocytic engulfment of the
PMN before membrane rupture occurs, resulting in spillage of cytotoxic
compounds into the extracellular environment[185;186].
Neutrophil apoptosis represents the first step in clearance of inflammatory
cells from areas of inflammation. In order to prevent accidental release of
cytotoxic compounds into the lung, alveolar macrophages can detect PMNs that
are undergoing apoptosis. Detection of these cells induces phagocytosis of
PMNs by macrophages. If not detected and engulfed, PMNs will undergo
secondary necrosis. This is associated with a loss in membrane integrity and a
release of cytotoxic compounds. This release is associated with detachment and
death of human lung epithelial cells in vitro[187]. Phagocytosis of senescent
PMNs prevents release of cytotoxic compounds into host tissue. Apoptotic cell
recognition by macrophages is still poorly understood, and several models have
been suggested[186;188;189]. Macrophages have a large capacity for engulfing
PMNs, which make them a major source of clearance for inflammatory cells.
Phagocytosis of microbial particles induces production of proinflammatory
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mediators such as TNFα, IL-1, etc., whereas phagocytosis of apoptotic PMNs by
macrophages has also been shown to inhibit proinflammatory cytokine
production, while increasing production of anti-inflammatory compounds such as
PGE2, TGF-β, and PAF[188]. These findings emphasize the importance of
apoptosis in the clearance of inflammatory cells and the resolution of
inflammation. This system of recognition is prone to disruption, however, and
studies have shown that recognition of apoptotic PMNs can be decreased in low
pH environments, or in presence of cationic molecules. During conditions such
as ARDS the presence of high numbers of PMNs can create such an
environment, which could be one explanation for progression of the disease
state[166].
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VII. Fatty Acids in ARDS
Experiments from our lab by Mancuso et al. demonstrated that feeding diets
supplemented with 20% fish oil for 21 days significantly attenuated lung
permeability and hypotensive effects compared with control animals fed diets
containing 20% corn oil for 21 days in LPS induced acute lung injury[72;73].
These experiments also demonstrated that diets containing fish oil were able to
significantly reduce concentrations of LTB4, PGE2, and TXB2 produced by
macrophages collected from BAL fluid of animals and stimulated in vitro by the
calcium ionophore, A23187. These reductions were accompanied by decreased
accumulation of AA in tissue phospholipids, along with increased EPA in animals
fed diets containing fish oil[71]. Further studies by Mancuso demonstrated that
fish oil diets could significantly reduce levels of myeloperoxidase activity in the
lung when compared with animals fed a corn oil diet with LPS acute lung injury.
Animals fed diets containing fish oil and administered LPS to induce lung injury
also exhibited a reduction in the number of PMNs found in the BAL fluid when
compared with animals fed the corn oil diet[72]. These studies culminated in
clinical trials where patients were fed a custom high fat, low carbohydrate enteral
nutrition formula containing a combination of fish and borage oils as well as
antioxidants. Patients fed this formula demonstrated a significant decrease in
PMN accumulation in recovered BAL fluid as compared with patients fed an
isocaloric, isonitrogenous diet deriving its main lipid content from corn oil.
Accompanying the reduction in PMNs, patients fed the fish and borage oil diets
demonstrated significant improvements in oxygenation, and significantly
decreased dependence on ventilatory support. These improvements resulted in
a decreased stay time in the intensive care unit for patients fed the fish oil and
borage oil supplemented diets when compared with controls[190]. Since
eicosanoid products have been shown to be involved in regulation of PMN
apoptosis, and their diets were shown to reduce the concentration of proinflammatory eicosanoid products interest was raised as to the role that these
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fatty acids might have on PMN lifespan[57]. Later work from our laboratory by
Gillis investigated the possible interaction of diet and apoptosis using the human
promyelocytic cell line HL-60[191;192]. The results of these experiments showed
that direct treatment of HL-60 cells with either EPA or GLA ethyl esters alone or
in combination would significantly decrease cell viability and that this decrease
was through an increase in apoptosis[192]. Since previous work from our
laboratory had demonstrated that decreased PMNs and symptoms of lung injury
from endotoxic rats were accompanied by a significant reduction in eicosanoid
products, we examined whether the effects of fatty acid treatment at inducing
apoptosis in HL-60 cells could be replicated by inhibiting the pathways of
eicosanoid metabolism[191]. These studies found that blockage of the 5-LO
pathway, but not the COX pathways could induce apoptosis, implying a critical
role for the products of 5-LO metabolism in the regulation of HL-60 cell
apoptosis. Taken together, these studies demonstrate the potential for n-3 fatty
acids to influence the course of the inflammatory response in ARDS, and suggest
that this impact could be due to an interaction between diet and neutrophil
viability.
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VIII.

Summary of Literature and Introduction to Current Study

Fatty acids of the n-6 and n-3 families are important substrates for the formation
of inflammatory mediators. The 20-carbon members of these families; AA and
EPA, respectively, are competitive substrates for storage in cell membrane
phospholipids and for the formation of eicosanoid products. Eicosanoid products
of AA are considered to be pro-inflammatory, and have been shown to have
numerous effects including the chemotaxis and activation of PMNs. Eicosanoid
products of EPA are less biologically active than those from EPA, and are
considered to be anti-inflammatory. The addition of n-3 PUFAs to the diet
reduces concentrations of n-6 PUFAs in the cell membrane and reduces the
production of pro-inflammatory n-6-derived eicosanoids.
It has been suggested that an increased intake of n-3 fatty acids into the
typical western diet may provide numerous health benefits. However, due to
concerns with safety and supplies of natural fish stocks these suggestions have
been left largely unmet. This has led to interest in identifying alternatives to fish
oil for increasing n-3 fatty acid content in the diet. Addition of ALA to the diet has
been explored, but the conversion of ALA to EPA has been shown to be
inefficient. Thus, there is doubt as to whether dietary supplementation with ALA
provides a suitable alternative to fish oil for increasing n-3 incorporation into
tissue. Recent developments in the agricultural industry have yielded crop plants
that are capable of producing SDA in appreciable quantities, providing a potential
renewable resource of n-3 PUFAs.
Dietary supplementation with n-3 PUFAs from fish oil has demonstrated
the ability to decrease eicosanoid concentrations and neutrophil accumulation in
BAL fluid in patients and animals with ARDS or LPS-mediated acute lung injury.
Reduction of neutrophil numbers in the lung has been correlated with improved
outcomes in both patient and animal models. It is not currently known if diets
containing n-3 fatty acids affect neutrophil numbers by reducing neutrophil
chemotaxis or by increasing neutrophil apoptosis.
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This thesis has been designed to test two hypotheses; first, to examine if
diets supplemented with SDA ethyl ester increases EPA content in liver
phospholipids and if this increase is similar to those observed in animals fed a
diet containing EPA. Second, if dietary supplementation with SDA or EPA will
impact the regulation of constitutive and endotoxin-induced survival in neutrophils
by influencing the rate of apoptosis in both cell states.
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I. Materials and Methods
Animals: Male Long-Evans Rats (N = 18) weighing between 200-250g were
acquired from Taconic (Germantown, NY). Animals were housed at the animal
care facility at The University of Tennessee Medical Center Knoxville at
temperature ~24º C and on a 12h light: dark cycle. After arrival at the animal
care facility, rats were fed Harlan/Teklad 22/5 Rodent Diet (W) 8640 (Harlan
Industries Indianapolis, IN) for 4 days before being placed into individual
metabolic chambers for the feeding period of the study. Fresh water was
provided ad libitum. Animal weights and urine volumes were recorded daily.
Food was withheld overnight before animals were killed. All animal procedures
were approved by The University of Tennessee Animal Care and Use Committee
and were in accordance with the NIH Guide for the Care and Use of Laboratory
Animals.
Diets: Animals were randomly divided into 3 dietary groups (n=6 animals/group)
and were fed 200 kcal/ kg body weight/ day for 14 days. All experimental diets
were based on a typical western diet with the following caloric distribution:
20.62% of calories from protein, 47.18% of calories from carbohydrates, and
32.19% of calories from lipids. This experimental diet mix was predicated on the
US17 diet formulated by the Monsanto corporation (St. Louis, MO)[1] (Table 3.1).
The experimental diets contained either 10g/kg (1%) eicosapentaenoic acid
(EPA, 20:5; n-3, 95% pure) and 1% Trisun (ACH Humko, Cordova, TN) high oleic
acid sunflower oil (OA, 18:1; n-9, 85% pure), or 10g/kg (1%) stearidonic acid
(SDA, 18:4; n-3, 85% pure) and 1% Trisun high OA sunflower seed oil. This
design allowed fatty acids to be added at the expense of Trisun high oleic acid
sunflower oil[1-3] without altering caloric density among diets. Control diet, or
OA diet, was prepared by adding 20g/kg (2%) Trisun to the base diet.
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Table 3.1:
Experimental Diet Composition

Component

EPA
(g/kg)
229
3
274
86
114
57
43
5
60
33
10
10
0
11
6
19
11
2
0.15
0.03
928
2124
1449
4501

SDA
(g/kg)
229
3
274
86
114
57
43
5
60
33
10
0
10
11
6
19
11
2
0.15
0.03
928
2124
1449
4501

4.501
4.501
Carbohydrates
Protein
47.2
20.6

4.501
Lipids
32.2

Casein
L-Cystein
Cornstarch
Maltodextrin 10
Sucrose
Cellulose
Cocoa Butter
Linseed Oil
Palm Oil
Safflower Oil
Sunflower Oil (Trisun)
20:5(n-3) ethyl ester (EPA)
18:4(n-3) ethyl ester (SDA)
Salt Mix RD-96
Dicalcium Phosphate
Calcium carbonate
Vitamin mix V134014
Choline bitartate
α-Vitamin E acetate
TBHQ
kcal/kg protein
kcal/kg carbohydrates
kcal/kg lipids
total kcal/kg
kcal/g chow
Energy distribution (%)

OA
(g/kg)
229
3
274
86
114
57
43
5
60
33
20
0
0
11
6
19
11
2
0.15
0.03
928
2124
1449
4501
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Diets had a final caloric density of 4.5kcal/g. All diets were mixed by hand under
yellow light, and daily feedings were aliquoted into whirl-pak (Nasco, Ft.
Atkinson, Wisconsin) containers, flushed with N2 gas to prevent peroxidation, and
stored at -80º C until time of use. Gas chromatography was used to confirm the
fatty acid content of each diet[1-3] (Table 3.2).
Cells: All chemicals were purchased from Sigma Chemical (St. Louis, MO)
unless otherwise noted. Neutrophils were obtained by lavage from the peritoneal
cavity after glycogen elicitation[4-6]. Rats were anesthetized with isoflurane
(Abbott Labs, North Chicago, IL) and given a 30ml intraperitoneal injection of 1%
type 2 oyster glycogen dissolved in 1x Dulbecco’s PBS without Ca2+ or Mg3+.
Animals were allowed to recover for 4h and then re-anesthetized with isoflurane.
A cardiac puncture was performed and animals were exsanguinated. The
musculature of the abdominal cavity was exposed through an incision in the skin
and peritoneal lavage was performed using a 30ml syringe fitted with an 18
gauge blunt tipped needle to flush the peritoneal cavity with 50ml of ice cold 1x
Dulbecco’s PBS without Ca+2 or Mg+3 and with 1mM ETDA (Fluka Chemical,
Switzerland) and 0.01% v/v heparin (American Pharmaceuticals Partners, Inc.,
Shaumburg, IL). Lavage fluid was briefly agitated by massaging the abdominal
wall and withdrawn from the opposite side. Fluid was pooled in a 50mL conical
centrifuge tube (Becton-Dickinson, Franklin, NJ) and peritoneal cells were
pelleted by centrifuging at 700 x g for 7min in a Sorvall RT6000B refrigerated
centrifuge (Sorvall, Newtown, CT). Supernatant was carefully aspirated and
contaminating red blood cells were removed by hypotonic lysis using 1ml
pyrogen free cell culture water. After 1 min of lysis, 0.5ml of 3x Dulbecco’s PBS
was used to restore tonicity[7]. Cells were then resuspended in 50ml of 1x
Dulbecco’s PBS. Cell number and viability were assessed using a Neubauer
hemacytometer and trypan blue dye exclusion assay. Glycogen elicitation
yielded > 98% pure neutrophil populations as evaluated during hemacytometry.
Cell concentrations were adjusted to1 x106 cells/ml. Cells for each incubation
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Table 3.2:
Experimental Diet Fatty Acid Composition.

Dietary Groups
OA
EPA
g/100g total fatty acids

SDA

Fatty Acid
12:0

0.36

0.33

0.34

14:0

0.56

0.52

0.53

16:0

26.09

25.21

25.15

16:1

0.17

0.17

0.16

17:0

0.13

0.12

0.12

18:0

12.75

12.16

12.13

18:1 (n-9)

35.06

31.2

31.21

18:2 (n-6)

20.23

19.82

19.69

18:3 (n-3)

2.1

2.05

2.05

18:4 (n-3)

ND

ND

5.26

20:0

0.56

0.54

0.53

20:1

0.14

0.13

0.12

20:4 (n-6)

ND

0.18

ND

20:5 (n-3)

ND

5.44

ND

22:0

0.24

0.2

0.2

22:6 (n-3)

0.13

0.11

0.11

ND indicates not detectable.
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were separated and placed into 15ml conical centrifuge tubes (Becton Dickinson
Labware, Franklin Lakes, NJ) and were pelleted by centrifugation at 700 x g for
7min and resuspended at 1x 106 cells/ml in RPMI 1640 without phenol red and
supplemented with 10% heat inactivated fetal bovine serum, 1% glucosamine,
and 1% penicillin/ streptomycin. Cells were transferred to 12x75mm
polypropylene tubes (Becton Dickinson Labware, Franklin Lakes, NJ) containing
pre-warmed media and allowed to equilibrate.
Cell Treatment and Incubation: Cells from each feeding group were incubated
for 20h in either the presence or absence of 1µg/ml of Salmonella enteritidis
lipopolysaccharide (LPS, Sigma Chemicals, St. Louis, MO). A positive control
for apoptosis was obtained by incubating cells for either 4 or 20h in presence of
5µM camptothecin (CAM, Sigma Chemicals, St. Louis, MO). All treatment and
control tubes were prepared in triplicate and contained a final concentration of
250,000 cells/ml. Atmosphere was maintained at 37º C and 5% CO2/ 95% room
air mix in a NAPCO 5410 incubator (Precision Scientific, Chicago, IL).
Flow cytometry: Cell preparation and staining for flow cytometric analysis of
apoptosis was performed using an Annexin-V FITC Apoptosis Detection Kit (BD
Pharmingen, San Diego, CA). At 0 and 20h, cells from control and LPS
treatment groups were pelleted by spinning at 700xg for 7 min using a Sorvall
RT6000B refrigerated centrifuge. CAM treated cells were pelleted at 4h or 20h
but otherwise were handled identically to other treatments. Supernatants were
carefully removed and cells were resuspended in 1ml of PBS containing 0.1%
bovine serum albumin (BSA). Cells were transferred to 2ml polypropylene tubes
and pelleted using a model 5415 D eppendorf centrifuge (Brinkmann Industries,
Westbury, NY). Supernatant was removed and 100µl of annexin-V binding buffer
(kit) was added to each tube. Cells were mixed by flicking the side of the tube
followed by addition of 5µl of annexin-V protein and 10µl of propidium iodide (PI)
(both from kit) in the dark. Cells were then allowed to incubate for 15 min at
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room temperature in the dark. Following incubation, 400µl of annexin-V binding
buffer was added to each tube. Cells were transferred to 12 x 75mm polystyrene
tubes (Becton Dickinson Labware, Franklin Lakes, NJ), placed on ice and kept in
the dark until analysis. Flow cytometry was performed using a Becton-Dickinson
FACScan flow cytometer and analyzed using Cell Quest software v. 1.2 (Becton
Dickinson, San Jose, CA). Unstained, PI positive/ annexin-V negative, and
annexin-V positive/ PI negative cells were used to adjust gain and compensation
levels, as well as to properly adjust scatter plot and gate settings of the flow
cytometer (figure 3.1). The main cell population was isolated based on size and
complexity from the forward scatter and side scatter dot-plot. This population
was liberally gated to encompass viable, necrotic, and apoptotic PMNs, while
excluding smaller aggregates and debris components. FL-1 represents a typical
histogram representation of annexin-V fluorescence, while FL-2 represents a
typical histogram of PI fluorescence. Annexin-V positive and PI positive cells
were defined by histogram markers. M1 represents cells that exhibit either
negative or dim fluorescence, which are considered negative for annexin-V or PI,
respectively. M2 represents brightly stained cells that are considered to be
positively stained for either annexin-V or PI. M3 region was used to calculate the
number of cells that were only dimly stained (data not shown). Figure 3.1 also
illustrates a typical scatter-plot of cell fluorescence. Each quadrant is labeled as
being either annexin-V +/- or PI +/-, and represents cell condition. Cells in the
lower left quadrant are considered viable since they were not stained with either
PI or annexin-V. The lower right quadrant contains cells that are PI negative and
annexin-V positive and are considered apoptotic. Cells in the upper right
quadrant are cells that are positively stained for both annexin-V and PI. Since
dual staining indicates cells with DNA damage representative of apoptosis as
well as PI permeable membranes these cells are defined as being secondary
necrotic cells. In vitro, secondary necrotic cells have been defined to be in the
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A.

(A) Flow cytometric representation of forward scatter versus side scatter.
1

Red cells in Region R1 represent gated cell population used for analysis.

Figure 3.1. Settings and Representative Report From Flow Cytometry Analysis
(A-D).
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B.

(B) Fluorescence histogram of Annexin-V
M1 represents unstained or dimly stained cells that were considered annexin-V negative.
M2 represents brightly stained cells that were considered
annexin-V positive.

C.

(C) Fluorescence Histogram of propidium iodide.
M1 represents unstained or dimly stained cells that were considered PI
negative.M2 represents brightly stained cells that were considered PI
positive.M3 was used to calculate dimly stained cells (data not shown).

Figure 3.1. Continued.
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D.

(D) Scatter-plot representation of cell staining.
PI- ANNEXIN – represents unstained viable cells.
PI- ANNEXIN + represents annexin stained apoptotic cells.
PI+ ANNEXIN + represents dually stained secondary necrotic cells.
PI+ ANNEXIN – represents PI stained necrotic cells.

Figure 3.1. Continued.
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phase following apoptosis[8]. Finally cells in the upper left quadrant are
considered to be necrotic, as their membranes have been permeablized to PI
without occurrence of DNA cleavage. The lower right and upper right quadrants
were also combined to determine the total number annexin-V stained cells
regardless of PI staining. These cells were considered to represent those both
actively undergoing apoptosis, as well as those that had previously died through
the apoptotic route. This data set was termed “cell death”.
DNA Laddering: Presence of apoptosis in peritoneal cells from animals from
each feeding group (n=2) was confirmed by agarose gel electrophoresis[9]. For
each gel 1x106 cells from 0h or from 20h treatment groups were transferred into
2ml snap-top eppendorf tubes. Cells were pelleted at 700 x g for 7min using an
eppendorf centrifuge, model 5415D (Brinkmann instruments, Westbury, NY), the
supernatant was carefully removed, and cell pellets were flash frozen in liquid
nitrogen. Cells were stored at -80º C until analysis. On day of analysis, cells
were allowed to thaw for ~5min and 20µl of lysis buffer (20mM EDTA
(Mallinckrodt, St. Louis, MO), 100mM TRIS, pH 8.0, 0.8% (w/v) sodium lauryl
sarcosine (Bioworld, Dublin, OH)) was added to each tube. Immediately
following addition of lysis buffer 10µL of 1mg/ml RNase/T1 cocktail mix (Ambion,
Austin, TX) was added, and samples were mixed and incubated for 75min at
37ºC. Proteinase K 10µl (Ambion, Austin, TX) was added to cell lysates which
were then incubated for 120min at 50º C. Samples were mixed with 5µl loading
buffer and loaded onto a 1.5% agarose gel. Gel was run for 200min at 30v in 1x
TAE buffer using Bio-Rad Mini-Sub Cell GT (Bio-Rad, Hercules, CA) and a
Fisher Biotech FB300 (Fisher Scientific, Pittsburgh, PA) power supply. Molecular
marker XIV (Roche, Manheim, Germany) was used as a reference for DNA
fragment size. Cells were exposed to a 4h CAM treatment as a positive control
for apoptosis. DNA bands were visualized using ethidium bromide (Promega,
Madison, WI) on a Fluorchem 8000 Imager (Alpha Innotech, San Leandro, CA).
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TUNEL Assay: Detection of apoptosis by TUNEL assay was performed using
the In Situ Cell Death Detection Kit, Fluorescein (Roche, Manheim, Germany). At
0h and for both control and LPS treatment groups at 20h approximately 20,000
cells were cytospun for 5 min at 500 rpm (Cytospin3, Shandon, England) and
placed onto glass microscope slides (Fisher Scientific, Pittsburgh, PA). Slides
were air dried and fixed for 1h using Carson’s solution. Slides were then rinsed
using PBS and placed in drying racks and stored until analysis. On day of
analysis, slides were rinsed with PBS and 100µl of cytofix/cytoperm solution
(Pharmingen, San Diego, CA) was applied. Slides were incubated for 20min at
4º C and washed with 100µl perm/wash buffer (Pharmingen, San Diego, CA).
Slides were rinsed with deionized water, allowed to air dry, and stained for
apoptosis using 50µl TUNEL reaction mixture (kit) and incubated for 60min at 37º
C in a humidified chamber. 100µl of Hoechst stain (Molecular Probes, Eugene,
OR) was applied to each slide as a counter stain to detect total DNA. Slides
were incubated for 30min at 37º and rinsed with PBS. Protective 12 x 50 – 1.5
glass coverslips (Fisher Scientific, Pittsburgh, PA) were applied using Dako
fluorescent mounting medium (Dakocytomation, Carpinteria, CA). Slides were
viewed using an Olympus BX51 fluorescent microscope (Olympus Optical Co.,
LTD., Japan) under both FITC and DAPI filters. Images were captured using a
Magmafire SP CCD camera (Optronics, Goleta, CA). Image overlay and
analysis was performed using Image-Pro Plus software v 4.5 (Media
Cybernetics, Silver Spring, MD).
Liver: Following peritoneal lavage a central incision was made along the linea
alba exposing the abdominal cavity. The portal vein was located and separated
from surrounding connective tissue; ligated using Silk suture (3-0, Ethicon,
Somerville, NJ), and liver was perfused with 30cc ice cold PBS using an 18
guage needle. Liver sections ranging from 1-1.5g were removed and placed in
50ml conical centrifuge tubes, labeled, and flash frozen using liquid nitrogen.
Liver sections were stored at -80º C until time of analysis.
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Total Liver Fatty Acid Extraction and Phospholipid Separation: Total liver fatty
acids were extracted using a modified Bligh and Dyer technique[10-12].
Approximately 200mg of liver from individual animals was placed in a tissue
homogenizer along with 1ml 0.9% cold saline/ 100mg liver. Tissue was
thoroughly homogenized and 0.8ml of homogenate was transferred into
125x16mm Teflon coated screw top tubes (Corning, New York, NY).
Chloroform:methanol (3ml,1:2) was added to each tube along with 44µg of 1,2diheptadecaenoic-sn-glycerol phosphorycholine (Matreya Biochemicals, Pleasant
Gap, PA) as an internal standard. Homogenate solution was vortexed and
incubated for 30 min on ice in the dark. Following incubation, 200µl saturated
NaCl and 1mL chloroform was added to each tube. Tubes were vortexed and
incubated for 15 min on ice in the dark followed by centrifugation for 4 min at
900x g to ensure complete phase separation. The bottom chloroform layer was
transferred to a 12x75mm borosilicate glass tube (Fisher Scientific, Pittsburgh,
PA) using a glass Pasteur pipette. The extraction and transfer process was
repeated and samples were completely evaporated under nitrogen. Once both
extractions had dried completely they were reconstituted in 50µl chloroform,
vortexed, and added to pre-scored silica gel 60 HP-TLC plates (Merck,
Darmstadt, Germany) for separation of the phospholipid portion by thin layer
chromatography (TLC). Plates were placed in a TLC chamber containing
approximately 1 inch of chloroform:methanol (8:1) as a mobile solvent system
and ran for 15 min. Plates were removed and allowed to dry fully under nitrogen.
The phospholipid portion of each lane was scraped onto weighing paper and
added to 16x125mm screw top tubes.
Analysis of Phospholipid Fatty Acids: Liver phospholipids were prepared for
analysis by gas chromatography (GC)[2;10;12]by first saponifying with 0.4ml of
0.5N NaOH/MeOH for 15 min in an 86º C water bath in tightly sealed 16 x 125
mm screw top tubes. Tubes were then removed from the water bath and allowed
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to cool. Fatty acids were methylated by adding 1ml of boron trifluoride/methanol,
tightly recapping tubes, and incubating in an 86º C water bath for 10 min.
Samples were removed from the water bath, allowed to cool, and acidified with
0.4ml of 0.7 N HCl in MeOH. Following acidification, fatty acid methyl esters
were extracted once again by adding 2ml of hexane and 2ml of saturated NaCl
solution to each tube. Tubes were vortexed and allowed to settle for
approximately 5 min for phase separation to occur. Samples were centrifuged for
4 min at 900 x g for complete separation. The hexane (top) layer was carefully
transferred to a new 12 x 75mm borosilicate tube for each sample. A second
hexane extraction was performed and pooled with the first and both extractions
were completely evaporated under N2 gas. Dried samples were reconstituted in
100µl of hexane and vortexed vigorously. Samples were analyzed using a
Hewlett-Packard model 5890 series II gas chromatograph equipped with flame
ionization detector and DB23 fused silica capillary column (0.25 mm i.d. x 30m x
0.25µm film; J&W Scientific, Folsom, CA). Fatty acid separation was achieved by
increasing temperature from 160-250º at a rate of 3.5º C / min using hydrogen as
the carrier gas. Gas chromatography standards 461 and 68B (Nu-Chek Prep,
Elysian, MN) were included in each analysis procedure. Retention times for the
known standards were used to identify fatty acid methyl esters.
Lipid Analysis of Diets: The fatty acid composition of each diet was confirmed
using gas chromatography. Approximately 50mg of diet was placed into a 16 x
125mm tube along with 3ml chloroform:methanol (8:1) and 44µg of 1,2diheptadecaenoic-sn-glycerol phosphorycholine as an internal standard and
incubated on ice in the dark for 30 min. Solid portions of food were separated by
centrifugation and fatty acids from diets were extracted using the modified Bligh
and Dyer technique[11] and analyzed using gas chromatography following the
same protocol as outlined for liver phospholipids.
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Statistical Analysis: Data were expressed as mean ± SEM. Fatty acid data were
analyzed by one-way ANOVA followed by Ryan-Einot-Gabriel-Welch based on
ANOVA F test (REGWF) to determine differences among groups. Analyses were
performed using CRUNCH v. 4.0 statistical package (Crunch Software Corp.,
Oakland, CA). Animal weight data were analyzed by repeated measures ANOVA
followed by Wilk’s Lambda multivariate post-hoc test. Flow cytometry data were
used to determine effect of LPS treatment, diet, and interaction between diet and
LPS treatment in altering the number of viable cells, cells undergoing early or late
apoptosis, or cell death after 20h. Flow cytometry data were analyzed using
repeated measures ANOVA followed by Wilk’s Lambda multivariate post-hoc
test. Analyses were performed using SPSS v. 13.0 for windows (SPSS inc.,
Chicago, IL). P≤0.05 was considered significant.
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I. Results
Animal Weights: Body weights were recorded daily and reported as percent of
body weight taken on the first day. Repeated measures ANOVA indicated no
differences in weight during the feeding period (figure 4.1).
Liver Fatty Acid Composition: Liver phospholipid fatty acid composition was
determined after 14 days of feeding and reported as mol % (table 4.1).
Alterations in liver phospholipids reflected fatty acid supplementation. As
compared with dietary OA, animals fed the EPA diet demonstrated a significant
decrease in tissue AA levels (p≤0.05). There was a significant increase in tissue
EPA content for animals in the EPA group, as compared with those from the OA
group (p≤0.05). EPA-fed animals demonstrated a significant increase in tissue
DPA, as compared with controls (p≤0.05). Supplementation of the diet with EPA
failed to increase DHA levels as compared with OA fed animals. EPA animals
exhibited a significant increase in total n-3 fatty acid content, as compared with
control animals (p≤0.05). This was accompanied by a significant decrease in
total n-6 fatty acid content of membrane phospholipids as compared with controls
(p≤0.05). These changes were reflected by an increased ratio of (n-3)/(n-6) fatty
acids for animals in the EPA group as compared with OA animals (p≤0.05). The
increased ratio of (n-3)/(n-6) PUFAs coincided with a significant increase in the
membrane phospholipid ratio of EPA/AA in animals from the EPA group as
compared with controls (p≤0.05).
Dietary SDA produced similar results to those observed in EPA-fed
animals in regards to fatty acid composition of membrane phospholipids. Dietary
SDA supplementation exhibited a slight, although not significant, decrease in AA
content of membrane phospholipids as compared with OA diets. SDA did,
however, produce a significant increase in phospholipid levels of EPA as
compared with dietary controls (p≤0.05). SDA also significantly increased the
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Table 4.1:
Fatty Acid Composition of Rat Liver Tissue After Feeding Experimental Diets for
2 Weeks.
Fatty Acid

OA (n =7)

EPA (n = 8)

SDA (n = 7)

16:0

16.08 ± 0.37

15.99 ± 0.41

15.93 ± 0.42

16:1

0.06 ± 0.03

0.10 ± 0.27

0.14 ± 0.03

18:0

26.04 ± 0.25

25.78 ± 0.33

26.07 ± 0.23

18:1 n-9

3.73 ± 0.2

3.50 ± 0.13

3.32 ± 0.23

18:1 n-7

1.55 ± 0.05

1.50 ± 0.05

1.49 ± 0.03

18:2 n-6

15.06 ± 0.55

16.41 ± 0.12

15.5 ± 0.51

18:3(n-6)

0.11 ± 0.02

0.11± 0.02

0.1 ± 0.02

18:3 (n-3)

0.09 ± 0.02

0.07 ± 0.02

0.08 ± 0.01

20:0

0.01 ± 0.01

0.02 ± 0.01

ND

20:1

0.07 ± 0.01

0.07 ± 0.02

0.08 ± 0.02

20:2

0.3 ± 0.05

0.29 ± 0.01

0.26 ± 0.01

20:3 n-6

0.56 ± 0.04

0.49 ± 0.02

0.52 ± 0.03

20:4 n-6

28.35 ± 0.56a

25.64 ± 0.39b

27.48 ± 0.47 a

20:5 n-3

0.21 ± 0.05a

1.18 ± 0.17 b

0.62 ± 0.07 c

22:4 n-6

0.30 ± 0.02a

0.15 ± 0.01 b

0.14 ± 0.04 b

22:5 n-6

0.14 ± 0.02a

0.04 ± 0.05 b

0.09 ± 0.02 ab

22:5 n-3

0.51 ± 0.04a

1.69 ± 0.10 b

1.03 ± 0.02 c

22:6 n-3

6.84 ± 0.36

6.96 ± 0.25

7.12 ± 0.42

Total (n-3) FA

7.65 ± 0.41a

9.9 ± 0.35 b

8.86 ± 0.37 b

Total (n-6) FA

44.52 ± 0.28a

42.84 ± 0.45b

43.83 ± 0.25 ab

(n-3)/(n-6) ra tio

0.17 ± 0.01a

0.23 ± 0.01 b

0.2 ± 0.01 c

0.05 ± 0.01 b
0.01 ± 0.00a
0.02 ± 0.00 a
EPA/AA ra tio
Data are expressed as mean mole % ± SEM. ND indicates not detectable.
Values with different superscripts indicate significant difference (p<0.05). n indicates number of animals.
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DPA content of membrane phospholipids of the liver as compared with animals
from the OA group (p≤0.05). Dietary supplementation with SDA did not result in
a significant increase in tissue DHA levels. Although diets containing SDA
significantly altered some of the n-6 fatty acids, these changes did not result in a
significant decrease of total n-6 levels as compared with controls. However,
there was a significant increase in the total n-3 PUFA content of membrane
phospholipids of SDA animals as compared with OA fed animals (p≤0.05). This
was reflected by a slight, but significant, increase in the n-3/n-6 fatty acid ratio in
membrane phospholipids of SDA-fed animals as compared with controls
(p≤0.05). SDA did not significantly alter ratio of EPA/AA in the membrane
phospholipids as compared with control animals.
Addition of SDA or EPA to the diet resulted in an increase in the amount of
EPA incorporated into membrane phospholipids in the liver. Dietary SDA was
approximately half as effective as dietary EPA at increasing membrane
phospholipid EPA levels. Diets supplemented with SDA were about two-thirds as
effective as those containing EPA at increasing tissue DPA content above those
observed in controls. Neither the SDA nor the EPA diet produced a significant
increase in tissue DHA levels.
DNA Laddering: During apoptosis DNA is degraded by endogenous DNases into

180-200bp fragments, and presents a distinct banding pattern when examined
using gel electrophoresis. In this study, gel electrophoresis was used to confirm
the presence of DNA cleavage, which is indicative of cellular apoptosis. Results
shown in Figure (4.2), although not quantitative, provide evidence that after 20h
of incubation a number of cells had undergone apoptosis. This banding was
present regardless of diet or treatment with LPS. The only lanes in which
banding patterns indicative of DNA fragmentation were absent were those
containing cells that were collected at 0h.
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Figure 4.2. Effect of Diet and LPS Treatment on DNA
Fragmentation.
Lanes: M=marker lane containing a 100bp ladder of DNA fragments
from 2642bp, 1500-100bp; 1=PMNs from OA fed animal at 0h
(negative control); 2=OA 20h –LPS; 3=OA 20h+ LPS; 4=OA cells 4h
+ CAM (positive control);5=EPA 20h –LPS; 6=EPA 20h +LPS;
7=SDA 20h –LPS; SDA 20 +LPS
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TUNEL assay: Examination of slides prepared with both TUNEL and Hoechst

stains confirmed the presence of apoptotic bodies among cell populations from
all feeding groups. Representative images from fluorescence microscopic
examination of stained slides are shown in figure 4.3. These images were
created by overlaying digital pictures of a single area of a microscope slide taken
under both DAPI and FITC filters. Hoechst stained cell nuclei were used to
provide a reference point for regions of the slide that were TUNEL positive.
Images shown were taken from slides prepared with cells that had been
incubated for 20h in either presence or absence of LPS. Gross examination of
slides indicated that treatment of cells with LPS for 20h led to an apparent
decrease in the amount of bodies that were positive for TUNEL stain. Slides of
cells treated for 20h with LPS also appeared to be more densely populated with
Hoechst positive bodies. Under gross examination, slides prepared with cells
from animals that were fed either the EPA or the SDA diets also appeared to
have fewer apoptotic bodies as compared with those from animals fed the OA
diet.
Flow Cytometry: The effect of LPS on viability, apoptosis, secondary necrosis,

and cell death in glycogen-elicited neutrophils after dietary treatment is shown in
Figure 4.4 (A-D). After 20h incubation diet did not significantly alter viability or
LPS-mediated viability in neutrophils. Because there was no interaction between
diet and neutrophil viability we examined whether treatment with LPS had any
effect on neutrophil survival, irrespective of diet. The effect of LPS treatment,
regardless of diet, on viability, apoptosis, secondary necrosis, and cell death are
shown in figure 4.5 (A-D). We show that, independent of diet, LPS significantly
increased viability and decreased cell death due to a decrease in apoptosis and
secondary necrosis. Since apoptosis, secondary necrosis, and cell death at 20
hours of incubation are directly related to freshly isolated (basal) values of these
same parameters (basal data not shown), the absolute differences between the
basal and 20 hr in absence and presence of LPS were calculated irrespective of
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A. 20h –LPS 100x

B. 20h +LPS 100x
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Figure 4.3. Fluorescence Images of TUNEL and Hoechst Stained Cells From
Each Feeding Group After 20h Incubation in Absence or Presence of LPS.
A. Oleic acid group 20h –LPS; B. Oleic Acid group + LPS; C. EPA group –LPS; D. EPA
group +LPS; E. SDA group –LPS; F. SDA group +LPS
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Figure 4.4. (A-D). Effects of Diet and LPS Treatment on Cell Viability, Apoptosis,
Secondary Necrosis, and Cell Death in Glycogen Elicited Peritoneal Neutrophils
at 20 Hours in Presence or Absence of LPS.
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(A-B) Effects of diet and LPS treatment on cell viability and apoptosis in
glycogen elicited peritoneal neutrophils at 20 hours in
presence or absence of LPS.
1

Mean ± SEM of cell population at 20h in presence or absence of LPS for
cell viability and apoptosis as measured using flow cytometry with propidium iodide and
annexin-V staining (N=6/group).
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(C-D) Effects of diet and LPS treatment on secondary necrosis and cell death
inglycogen elicited peritoneal neutrophils at 20 hours in
presence or absence of LPS.
1

Mean ± SEM of cell population at 20h in presence or absence of LPS for
secondary necrosis and cell death as measured using flow cytometry with propidium iodide and
annexin-V staining (N=6/group).
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Figure 4.5 (A-D). Effect of LPS on Viability, Apoptosis, Secondary Necrosis, and
Cell Death Following 20h Incubation.
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(A-B) Effect of LPS on viability, apoptosis, secondary necrosis, and cell death
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*Values sharing different superscripts are different (p≤0.05)
Mean ± SEM of % cell population as measured by flow cytometry using annexin-v and propidium
iodide staining (N=18).
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Mean ± SEM of % cell population as measured by flow cytometry using annexin-v and propidium
iodide staining (n=18).
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diet. Figure 4.6 (A-C) shows that apoptosis, secondary necrosis, and cell death
were significantly decreased in the presence of LPS after correction, or
normalization, for basal values and are in agreement with the findings shown in
Figure 4.5 (A-D).
The effect of dietary treatment on viability, apoptosis, secondary necrosis
and cell death of freshly extracted glycogen-elicited neutrophils is shown in
Figure 4.7 (A-D). These results show that after two weeks of dietary treatment
there were no significant changes in viability, apoptosis, secondary necrosis, and
cell death between the groups. It is important to note that although it appears
that secondary necrosis and cell death with EPA were increased as compared
with OA, statistical significance was not reached (P = 0.053). Since apoptosis,
secondary necrosis, and cell death at 20 hours of incubation are directly related
to the basal values of these same parameters, the absolute differences between
basal and 20 hr incubations in the absence and presence of LPS were calculated
for each dietary treatment group. The results indicate that neither SDA nor EPA
significantly affected viability, apoptosis, and secondary necrosis as compared
with OA in the absence or presence of LPS (Figure 4.8 (A-D)).
Although, there appears to be an increase in cell viability with EPA and SDA as
compared with OA in the presence or absence of LPS, these changes were not
significantly different (p=0.069)
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Figure 4.6. Effect of LPS on the Absolute Difference Between 0h and 20h for
Apoptosis, Secondary Necrosis, and Cell Death
Following 20h Incubation.
*Values sharing different superscripts are different (p≤0.05)
Mean ± SEM of the difference of cell population % from time 0h for apoptosis, secondary
necrosis, and cell death as measured using flow cytometry with propidium iodide and annexin-V
staining (N=18).
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Figure 4.7 (A-D). Effect of Diet on Cell Viability, Apoptosis, and Secondary
Necrosis in Glycogen-Elicited Peritoneal Neutrophils at 0 Hours.
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measured using flow cytometry with propidium iodide and annexin-V staining (N=6/group).
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(C-D) Effect of diet on secondary necrosis and cell death in glycogen-elicited
peritoneal neutrophils at 0 hours.
*Values sharing different superscripts are different (p≤0.05)
Mean ± SEM cell population % at 0h for cell death as measured using flow cytometry with
propidium iodide and annexin-V staining (N=6/group).
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Figure 4.8. (A-D). Effect of Diet on the Absolute Difference From Time 0h to 20h
for Viability, Apoptosis, Secondary Necrosis and Cell Death Following 20h
Incubation in Presence or Absence of LPS.
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(A-B) Effect of diet on absolute difference from time 0h to 20h for viability and
apoptosis following 20h incubation in presence or absence of LPS.
1

Mean ± SEM of the difference of cell population % from time 0h for apoptosis, secondary
necrosis, and cell death as measured using flow cytometry with propidium iodide and annexin-V
staining.
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(C-D) Effect of diet on absolute difference from time 0h to 20h for secondary
necrosis and cell death following 20h incubation in presence or absence of LPS.
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Mean ± SEM of the difference of cell population % from time 0h for apoptosis, secondary
necrosis, and cell death as measured using flow cytometry with propidium iodide and annexin-V
staining.
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I. Discussion

The results of this study show that feeding purified ethyl esters of EPA and SDA
in the context of a typical western diet for 14 days resulted in the incorporation of
n-3 fatty acids in the phospholipids of rat liver. The diets used in this study were
designed based on the macronutrient and fatty acid composition of a typical
western diet. Petrik et al[1] showed that by using oleic acid (OA) as the control
fatty acid, they could maintain constant levels of n-6 fatty acids in their diets.
They previously showed that OA is neutral in respect to prostaglandin
formation[2]. OA is an n-9 fatty acid, and is not interconvertible with n-6 or n-3
fatty acids. We also designed our experimental diets using OA as the control
fatty acid. Our experimental diets were supplemented with purified ethyl esters
of EPA or SDA instead of fish or an SDA containing oil such as echium oil[3].
Thus, our design allowed us to vary fatty acid intake in the context of the typical
western diet and avoid the problems of one dietary oil substituted for another.
The results of this study can be attributed to substitution of one fatty acid for
another.
Dietary supplementation with purified SDA and EPA ethyl esters resulted
in a significant increase in tissue phospholipid incorporation of n-3 PUFAs, such
as EPA and DPA, in liver. We found that supplementation with SDA resulted in
a significant increase in tissue EPA levels as compared with control animals, and
that this increase was about one-half of that seen when animals were fed EPA.
SDA was also effectively converted and stored as DPA, as compared with control
animals. This increase was about two-thirds as effective as that demonstrated
by the inclusion of EPA in the diet. Neither EPA nor SDA provided by diet were
metabolized to form DHA in the membrane phospholipids. These results are
consistent with others that report either a lack of or very low conversion of either
SDA or EPA to DHA[3;4]. This lack of conversion could be due either to the low
level of activity of the ∆6 desaturase enzyme, or the presence of ALA in our basal
US17 diet mix. In mammalian cells the conversion of DPA to DHA is not a direct
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one. Instead, DPA is first metabolized by two rounds of elongation to form 24:5n3. The ∆6 desaturase enzyme then desaturates 24:5n-3 to 24:6n-3. The 24
carbon chain length fatty acid is then shortened by β-oxidation to form DHA[5].
This pathway is referred to as the “Sprecher pathway”. The reaction rate of this
pathway is slow, and it has been reported that DPA is preferentially used as a
substrate for β-oxidation to form EPA rather than being metabolized to DHA[6].
This may provide one possible explanation for the lack of DHA accumulation in
liver phospholipids of our animals. The presence of ALA in our basal US17 diet
may provide an alternative explanation for the lack of significant increase in
tissue DHA seen in animals fed EPA or SDA as compared with controls. DHA
plays an important role in formation of the cell membrane, and because of this
shorter n-3 fatty acids are converted to DHA until the membranes become
saturated, only then is it used to form EPA or DPA. This leads to the possibility
that our basal diets may have provided enough ALA to saturate the concentration
of DHA in the cell membranes regardless of the addition of EPA or SDA.
Studies that suggest that the inclusion of n-3 fatty acids in the diet can
have beneficial effects on health aspects from cardiovascular function to
inflammation[7-9]. As previously mentioned the American Heart Association has
recommended an increased intake of n-3 fatty acids as a means to reduce the
risk for heart disease[10]. It has also been accepted that nutritional formulas
containing n-3 fatty acids may be useful as therapeutics for critically ill patients in
numerous disease states[11;12]. Most evidence for the benefits associated with
n-3 fatty acids applies to the long-chain members of the n-3 family EPA and
DHA, both of which occur in fish and fish oil. Suggestions that patients or
communities at large increase intake of fish are problematic for numerous
reasons, including; consumption of contaminated fish, food related allergies,
general resistance to dietary change, and limitations on natural fish stocks[8;13].
Given the utility of n-3 fatty acids in human health and nutrition, identification of a
suitable alternative source for dietary n-3 fatty acids is urgently required.
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The use of the ∆6 desaturase precursor fatty acid ALA may be used as an
alternative means to increase tissue EPA levels; however, the conversion from
ALA to EPA is too inefficient to be a practical suggestion[4;14]. Conversion of
ALA to EPA is a three step enzymatic process, and it has been suggested that
the first step in this metabolism, the ∆6 desaturase enzyme, may be the rate
limiting step in the conversion[15]. The inefficiency of this conversion process
has driven an interest in the use of SDA, which is the fatty acid product of ∆6
desaturase activity on ALA, as a possible source for increasing tissue EPA[4].
Feeding oil blends containing SDA can efficiently increase membrane
phospholipid n-3 content [3;16;17]. Studies in which SDA was added to cell
culture also resulted in incorporation of EPA and DPA into cell membranes[18].
As a result, agricultural companies have been working towards designing plant
species that can produce high levels of SDA in their seeds in hopes of providing
a sustainable alternative source for increasing tissue content of beneficial n-3
fatty acids[19].
Results from our current study confirm that addition of purified EPA ethyl
esters to the diet can increase tissue content of EPA and DPA, but not DHA.
These findings also demonstrate that dietary supplementation with SDA can
significantly increase content of EPA and DPA, but not DHA in liver membrane
phospholipids in a comparable fashion as animals fed a diet containing EPA.
These findings suggest that dietary supplementation with SDA might provide a
reasonable alternative to EPA provided by diet to increase the accumulation of
beneficial n-3 fatty acids in tissue phospholipids.
Animals were fed 200 kcal·kg-1·day-1 and diets were typically fully
consumed by the following day. Body weights were measured daily, and
although it appears that there is a slight decrease in body weight for SDA fed
animals as compared with the other dietary groups, this difference was not
significant. This was an interesting trend as SDA animals readily consumed their
food, which rules out a dietary preference. SDA animals also had similar starting
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body weights, and there were no obvious physical differences among animals in
this feeding group and those in the EPA and OA groups.
In order to ensure that our experimental model was appropriate for
detecting apoptosis we utilized two independent tests, TUNEL and gel
electrophoresis, to look for presence of apoptotic bodies and hallmark DNA
banding patterns, respectively. Although not quantitative, our gel electrophoresis
experiments provided evidence that cells were indeed undergoing apoptosis after
20h, regardless of LPS treatment. Prepared slides from all feeding groups
contained bodies that fluoresce positively for TUNEL stain following 20h
incubation. Regardless of feeding group, slides containing cells that were
incubated in presence of LPS appeared to posses fewer TUNEL positive bodies
than their untreated counterparts. Both of these tests provided evidence that
cells were undergoing apoptosis. Fluorescence microscopy also showed that
LPS reduced apoptosis.
Our results show that diet did not significantly affect neutrophil viability
following 20h incubation in absence or presence of LPS. LPS is a well known
activator of neutrophils and increases neutrophil lifespan[20]. The lack of
difference among dietary groups is not likely due to fault with LPS treatment, as
we tested whether our LPS model was sufficient to induce changes in neutrophil
lifespan, regardless of diet. We found that, irrespective of diet, LPS increased
neutrophil viability, and that this increase in viability was through a reduction in
apoptosis, secondary necrosis, and cell death. Furthermore, we found that in
freshly extracted neutrophils, secondary necrosis and cell death appeared to be
increased in the EPA group, but this increase failed to reach significance
(p=0.053). Although, these effects were probably due to the small sample size
and high variability, there is a close association between basal viability,
apoptosis, secondary necrosis, and cell death. Because of this association we
normalized the data by calculating the absolute difference between basal
neutrophils and those incubated for 20h in absence or presence of LPS. We
ensured that the calculation had not altered the LPS treatment by comparing the

141
results shown in Figure 4.5 (A-D) with those in Figure 4.6 (A-C). Results from
both figures showed that the addition of LPS resulted in decreased apoptosis,
secondary necrosis, and cell death. We found that the lack of dietary interaction
was also probably not due to differences in basal neutrophils, as normalization
did not produce any significant changes among dietary groups regarding
neutrophil viability in absence or presence of LPS. Analysis of normalized data
revealed a trend towards an increase in viability in EPA and SDA animals as
compared with OA animals. Although this trend failed to attain significance
(p=0.069), this could be a dietary effect, as power analysis suggested the
possibility of a statistically significant increase in viability with the addition of
approximately 15 animals.
Despite numerous studies that demonstrate definitive health benefits from
diets containing n-3 fatty acids, mainly attributed to EPA or DHA found in fish oil,
and a large body of literature demonstrating the positive effects of n-3 PUFAs as
therapeutic agents for inflammatory disorders, such as sepsis and ARDS, there
is a growing concern in the literature regarding safety of feeding n-3 fatty acids
as a means of controlling inflammation[21]. Several of these studies indicate that
feeding high levels of n-3 fatty acids can lead to an immuno-compromised state
by decreasing ability of the host to respond to infection[22;23]. PMNs play a vital
role at maintaining host immunity, and have been described as being the first
response to bacterial infection. Our current study may be of interest in light of
these recent papers that have questioned the safety of dietary supplementation
with n-3 PUFAs because of the potential to induce an immunocompromised
condition in subjects[21]. Studies discussing the effect of n-3 fatty acids and
immunosuppression have shown that long-term feeding (28d) of diets containing
high levels of fish oil (18% by weight) leads to a diminished host response to
bacterial challenge[22;23].

Our current findings show that EPA or SDA does

not significantly alter neutrophil lifespan or LPS-mediated neutrophil survival.
These findings show that 1% EPA or 1% SDA will not interfere with the ability of
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neutrophils to increase cell survival in response to bacterial products such as
LPS.
One of the objectives of this study was to investigate the hypothesis that
the beneficial effects of dietary supplementation with n-3 PUFAs observed by
Mancuso et al[24] was due to an attenuation of LPS-mediated PMN survival.
The increased rate of apoptosis would facilitate a faster clearance of
inflammatory cells from pulmonary tissue, thereby attenuating PMN
accumulation. In this study SDA and EPA did not significantly increase PMN
apoptosis or attenuate LPS mediated PMN survival. Previous work by Gillis et
al[25] suggested that diet might interact with cell viability by increasing apoptosis,
and that this increase in apoptosis may be the reason for the muted PMN
response observed in ARDS patients, and animal models of ALI previously
described by our laboratory[25;26]. However, findings from our current study do
not support this hypothesis. There could be several reasons for the differences
observed in our current work and previous results by Gillis et al[26]. First, HL-60
cells are a promyelocytic human leukemia cell line that has been adapted for use
as a model of PMN function[27] . N-3 fatty acids such as EPA have been
reported to have anti-tumorigenic properties, and decrease viability in a number
of cell lines at least in vitro[1;28-32]. One review reports that in over 100 cancer
cell lines, the addition of PUFAs to cell culture could reduce cell proliferation, or
induce apoptosis, while having little or no effect on normal cells[33]. Thus, the
increase in apoptosis observed in earlier studies from our laboratory may have
been complicated by the anti-carcinogenic action of PUFAs. Differences
between the findings from this study and those previously reported could also be
due to a difference in treatments. HL-60 cell culture work from our lab was
dependent on the addition of PUFAs directly to cell media. This could also
induce unanticipated effects as studies have reported that some of the cytotoxic
effects of n-3 PUFAs may be due to the formation of lipid peroxidation products
in vitro[34].
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These findings suggest that there may be other factors besides
apoptosis involved in the beneficial effects observed in the studies by
Mancuso[24]. A possible alternative mechanism for the reduction of PMN
concentration in BAL fluid of ARDS patients fed nutritional formulas containing
fish oil may be due to a reduced potential of alveolar macrophages to recruit
circulating PMNs to pulmonary tissue by a reduction of LTB4 synthesis. LTB4 has
been shown to be a potent attractant of PMNs to pulmonary tissue[35]. It has
also been shown that LTB4 is increased in the sputum of patients with COPD and
ARDS, which results in an increased chemotactic potential for PMNs[36]. The
importance of LTB4 as a signaling molecule in the lung is further emphasized by
the fact the alveolar macrophages have been shown to be capable of an
increased production of leukotrienes upon stimulation as compared with nonalveolar macrophages and monocytes, and that alveolar macrophages
preferentially produce leukotriene products of eicosanoid metabolism[37].
Stimulated alveolar macrophages also preferentially metabolize EPA as
compared with AA[38;39]. Previous work from our laboratory demonstrated a
significant reduction of LTB4 concentrations in BAL fluid of animals and patients
with ALI or ARDS fed nutritional formulas containing fish oil[24;40]. Reduction in
LTB4 could lead to a decreased chemotactic potential of resident alveolar
macrophages, resulting in a decreased influx of PMNs rather than an attenuated
lifespan of recruited PMNs.
One of the limiting factors of our current study was that we only examined
the effect of feeding 1% EPA or 1% SDA for 14 days. For future studies it would
be of interest to explore a dose-response of SDA and EPA on both membrane
phospholipid profiles as well as PMN function. Feeding fatty acids at different
concentrations and for different lengths of time might help clarify the differences
and similarities between SDA and EPA, and further strengthen the case for SDA
as a substitute for dietary EPA. An extension of current study conditions to
include more animals in each feeding group may also elucidate whether diet
supplemented with 1% EPA or 1% SDA is influencing PMN lifespan by

144
increasing PMN viability and LPS-mediated cell survival.

Given the importance

of LTB4 in the sequestration of PMNs to pulmonary tissue, it would also be
worthwhile to examine the chemotactic potential of alveolar macrophages
following dietary supplementation with EPA and SDA, as well as the ability of
PMNs with preloaded cell membranes to respond to chemotactic stimuli.
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Part 6
Conclusions
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I. Conclusions

Based on findings from these experiments it can be concluded first, that the diets
supplemented with SDA ethyl ester increased EPA and DPA, but not DHA
content in the liver. These findings were similar to those observed in animals fed
diets containing purified EPA ethyl ester, which increased membrane
phospholipid concentrations of EPA and DPA, but not DHA in liver. These
findings lead to the acceptance of our first hypothesis that diets supplemented
with purified SDA ethyl ester increased EPA content in liver phospholipids and
the increase was similar to that observed in animals fed diets containing EPA
ethyl ester.
It is concluded, second, from these findings that the addition of 1% EPA or
1% SDA to the diet does not alter viability, apoptosis, secondary necrosis, or cell
death in glycogen-elicited peritoneal neutrophils in absence or presence of LPS
in the rat. This leads us to reject our second hypothesis that dietary
supplementation with SDA or EPA will impact the regulation of constitutive and
LPS-induced survival in rat glycogen-elicited peritoneal neutrophils by influencing
the rate of apoptosis in both cell states.
The significance of this study is that it provides evidence that dietary SDA
provides an alternative to EPA as a means to increase the concentration of EPA
and DPA in liver membrane phospholipids. This study also provides evidence
that the inclusion of 1% EPA or 1% SDA in the diet does not lead to an increase
in constitutive neutrophil apoptosis and will not interfere with the ability of
neutrophils to respond to bacterial endotoxin by increasing cell lifespan. This
indicates that the addition of 1% EPA and 1% SDA to a standard western diet will
not lead to an immunocompromised state.
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